Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 211 Publications

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 21(10):1163-71

PubMed: 26390243 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Haematologica, 2019, 104(11):2225-2240

PubMed: 30819918 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )
Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

NMR Biomed, 2019, 32(2):e4044

PubMed: 30561869 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Pharmacol Res, 2019, 139:524-534

PubMed: 30366100 ( click the link to review the publication )

Medicina (Kaunas), 2019, 55(2)

PubMed: 30700046 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30652970 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):153

PubMed: 30012171 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )
Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Cancer Res, 2018, 78(10):2705-2720

PubMed: 29490948 ( click the link to review the publication )

J Virol, 2018, 92(10)

PubMed: 29343578 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cell, 2018, 174(3):536-548.e21

PubMed: 29961578 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )
Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(1):27-35

PubMed: 26575826 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )
EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(39):23725-37

PubMed: 26269591 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )
J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )

Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )
FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )

Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )
J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )

PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )
PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )

Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	MWrLbY5ie2ViQYPzZZk>		NUjEU402OSCq	MnHMSG1UVw>?	MlvrZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	Ml:1NVE6PjB2OEm=
Friend leukemic cell	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrWOVAh\|ryP	Mm\CO\|IhcA>?	MVjEUXNQ	NUC0NWwzUUN3ME2wMlk6KM7:TR?=	MV2xNlExQTlzMx?=
K562	M13WbWtqdmG\|ZTDBd5NigQ>?		M{XWVFYhcA>?	MYLEUXNQ	M1vwT2lvcGmkaYTpc44hd2ZiaIXtZY4hcGm\|dH;u[UBl\WGlZYT5cIF{\SBqbXn4eJVz\SCxZjDISGFEOSCjbnSgTGRCSzJrIIfpeIghUUN3MDDv[kAxNjBzIN88US=>	MXGxNlQyQTN6MB?=
HT1080	NYTRemRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnS0O\|IhcA>?	Mn7DSG1UVw>?	NIDUXHNKSzVyPUKuOEDPxE1?	MkTyNVIzPzBzN{W=
H1299	NFP5OHRMcW6jc3WgRZN{[Xl?		M3zJWlIxKG2rbh?=	NYe0ZYVETE2VTx?=	MkHTTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	MXqxOFUzOTR{Mh?=
H1299	NFnD[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NY[xUnl{PzJiaB?=	M1S4PGROW09?	MYXJR\|UxRTdwMkSg{txO	NV;PbJdCOTR3MkG0NlI>
HeLa	M4LLdWtqdmG\|ZTDBd5NigQ>?		MlfSN\|AhdWmw		MYTJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	Mo\6NVU3ODN7NEm=
LOX-IMVI	M1S1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVP0doNnPDhiaB?=		M4G4NmlEPTB;MT6zJO69VQ>?	NWX4d4V1OTV5MUW0O\|A>
NCI-H226	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVHx[lNFPDhiaB?=		MWfJR\|UxRTJwNjFOwG0>	NW\QO5VjOTV5MUW0O\|A>
RXF-631L	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWO0PEBp		NV7J[3V[UUN3ME2yJO69VQ>?	M4fqeVE2PzF3NEew
SNB-78	NGXvblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2TOWFQ5KGh?		M1X1cmlEPTB;MU[g{txO	NVrJU4lLOTV5MUW0O\|A>
St-4	NV7UVI54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWG0PEBp		MUjJR\|UxRTVwMjFOwG0>	M331S\|E2PzF3NEew
ARP1	NI\C[WxHfW6ldHnvckBCe3OjeR?=	NHvvUYszKM7:TR?=	MWW2JIg>		NX7tfVh3UW6mdXP0bY9vKG:oIGCyNXdCTjFiZ3Xu[UBmgHC{ZYPzbY9v	NWjQ[FFPOTR5M{S4NFY>
CEM	NVr6cItQU2mwYYPlJGF{e2G7		MkPUNUBp	M3rzdmROW09?	NX61V2oxUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlM{KM7:TR?=	NWDhcZZzOTZ2MkCwOlQ>
HCT15	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVy0PEBp		M3L0bGdKPTB;MD64NkDPxE1?	MnvNNVY4OjN{Mke=
NCI-H23	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFX3NYk1QCCq		NFLF[mhIUTVyPUCuPVIh\|ryP	Ml30NVY4OjN{Mke=
GM15850	MnHlT4lv[XOnIFHzd4F6	NF3SSIwzNjVizszN	M3n4XFk3KGh?	NVvmVnl2TE2VTx?=	M4nYeGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIx6e2mwZTCxOEBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	MWOxOlkzOTN4Nx?=
GM15850	NUf2Zm5[U2mwYYPlJGF{e2G7	M4\sXlIvPSEQvF2=	NXjIeY17QTZiaB?=	NWD5XYxzTE2VTx?=	NI[0XmJKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NGrkZY8yPjl{MUO2Oy=>
GM15850	NXX2XnlyU2mwYYPlJGF{e2G7	NUXGe3NVOi53IN88US=>	MUC5OkBp	NUXjfodvTE2VTx?=	NVPTR3U3UW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFEzKGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	NVzWRoZCOTZ7MkGzOlc>
GM15850	NXfHXlhOU2mwYYPlJGF{e2G7	MlTqNk42KM7:TR?=	NGjKU4k6PiCq	NWjJbWluTE2VTx?=	MXHJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKMzDsfZNqdmViOTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	MmjlNVY6OjF\|Nke=
GM15850	M1KyO2tqdmG\|ZTDBd5NigQ>?	MmO0Nk42KM7:TR?=	Mmj4PVYhcA>?	M4j0RWROW09?	MVjJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViODDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	MlXRNVY6OjF\|Nke=
GM15850	MmPQT4lv[XOnIFHzd4F6	NGfhcWwzNjVizszN	NHTBc5E6PiCq	MXTEUXNQ	NX\wco9uUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M4q3dFE3QTJzM{[3
U937	M2fV[WZ2dmO2aX;uJGF{e2G7	NVHEe2ZlPSEQvF2=	MXmyOEBp	NGnlWodFVVOR	MVPD[YxtKGO7Y3zlJIFzemW\|dDDifUBi[2O3bYXsZZRqd25iYYSgV{9IOi:PIIDoZZNm	MVSxO\|AxPDdzOB?=
H661	M{TydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGPyRpE1QCCq		MoPwTWM2OD1zIN88US=>	MYexO\|E2PzByOR?=
U937	MULGeY5kfGmxbjDBd5NigQ>?	NUD4TVkzPSEQvF2=	MmPVNlQhcA>?	Mk\SSG1UVw>?	NF7s[VFKdmO{ZXHz[UBqdiCqaYP0c45mKEh\|IHHj[ZR6dGG2aX;u	Ml;QNVc1PDd5NUC=
U937	MlTPSpVv[3Srb36gRZN{[Xl?	NUHTPGRCOSEQvF2=	NVrqeI46OjRiaB?=	MYLEUXNQ	M2\VNGVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	NGfGS40yPzR2N{e1NC=>
RAW264.7	M2PneGZ2dmO2aX;uJGF{e2G7	M4XmcVExKM7:TR?=	NX72eZZIOjSq	M1u2UpdifGW{	M2e3N2lvcGmkaYTpc44hd2ZiTGDTMZN1cW23bHH0[YQhXE6IYXzwbIEheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE44PiEQvF2=	MYCxO\|Q4PzVzOB?=
RAW264.7	M2jU[mZ2dmO2aX;uJGF{e2G7	MUOxNEDPxE1?	M1vIelI1cA>?	NVv1S3A5f2G2ZYK=	NX3SPWdiUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCQTzDwdo9lfWO2aX;uJJdqfGhiSVO1NEBw\iBzLki4JO69VQ>?	M{DweFE4PDd5NUG4
SC9	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGHDb4M1QCCq		Moe0TWM2OD1yLk[wOkDPxE1?	Mn;zNVc2ODd{MUm=
ST14A	NGXGflRHfW6ldHnvckBCe3OjeR?=	NWXiZ4NZPSCwTR?=	NHK3c3E4OiCq		NULRUGJIUW6lcnXhd4UhcW5iUlXTWE9PWlOIIH3SUmEh\XiycnXzd4lwdg>?	NX\wbpdiOTd3NkW5PVM>
ST14A	M2HRfGZ2dmO2aX;uJGF{e2G7	NGjpZoI2KG6P	MknYO\|IhcA>?		Ml;PTY5kemWjc3WgbY4hTTKIMTDtVm5CKGW6cILld5Nqd25?	MkHGNVc2PjV7OUO=
PANC1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmxJO69VQ>?			NGr6XHlKSzVyPUCuOFUh\|ryP	MnGxNVc2QDh5NES=
PANC1	NELrbnJHfW6ldHnvckBCe3OjeR?=	NH7p[pUyKM7:TR?=	MofMNlQhcA>?		Mmm4TY5kemWjc3WgbY4heDJzV1HGNU9EUVBzIHflcoUh\XiycnXzd4lwdg>?	NGWzNVkyPzV6OEe0OC=>
PANC1	NI[0WmFHfW6ldHnvckBCe3OjeR?=	MVOxJO69VQ>?	NXrxWYFyOjRiaB?=		M2Kzc2lv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	Mk\RNVc2QDh5NES=
PT45	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PSUWlEPTB;NDFOwG0>	NVTMTWJuOTd3OEi3OFQ>
ACHN	NHvmcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWWyNUBp		NFfZN\|FIUTVyPUCuOlUh\|ryP	NX3lRlhsOTd4NkK2NFY>
PC3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnnaNlEhcA>?		NH7tZnVIUTVyPUCuO\|Eh\|ryP	MXixO\|Y3OjZyNh?=
A431	MkDVR5l1d3SxeHnjJGF{e2G7		Mon3O\|IhcA>?		NUX4eHUxUUN3ME20MlIh\|ryP	M{f5T\|E4PjlzN{[z
Cal27	M2T5OWN6fG:2b4jpZ{BCe3OjeR?=		M3X4[\|czKGh?		NWTKVHFxUUN3ME2zMlIh\|ryP	MVmxO\|Y6OTd4Mx?=
CCRF-CEM	NVn2ZoloS3m2b4TvfIlkKEG\|c3H5		M4rvNVczKGh?		NGroW\|NKSzVyPUCuPEDPxE1?	M{H3Z\|E4PjlzN{[z
EOL1	NXzGXZV2S3m2b4TvfIlkKEG\|c3H5		M2S3Z\|czKGh?		MYLJR\|UxRTFizszN	NEPLR4YyPzZ7MUe2Ny=>
Hec-1-A	NYXzXohtS3m2b4TvfIlkKEG\|c3H5		NYraOXVNPzJiaB?=		NWHTSXFrUUN3ME2xJO69VQ>?	NF63NIQyPzZ7MUe2Ny=>
HeLa	MWfLbY5ie2ViQYPzZZk>	MYKxNEDPxE1?	M2WzeVMxKG2rbh?=	NHn0VJdFVVOR	NF7JeGhKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGhFSUNzIIfpeIghUUN3MDDv[kAxNjB{IN88US=>	NHu3[FYyPzZ7MUe2Ny=>
RKOp21	MmO1R5l1d3SxeHnjJGF{e2G7		NYTieXhQPzJiaB?=		NUf5TohwUUN3ME2xMlc3KM7:TR?=	NV7GdpZOOTd4OUG3OlM>
Saos2	NU\sdYxVS3m2b4TvfIlkKEG\|c3H5		NWjUNWVqPzJiaB?=		M1XEW2lEPTB;Mj6zJO69VQ>?	NV60WldMOTd4OUG3OlM>
SK-OV-3	NV7HT5JWS3m2b4TvfIlkKEG\|c3H5		MYm3NkBp		NGq4XHVKSzVyPUKuNkDPxE1?	MkjRNVc3QTF5NkO=
U87MG	NFXhO5JEgXSxdH;4bYMhSXO\|YYm=		MXy3NkBp		NVvDN2FOUUN3ME2xNUDPxE1?	M1yxfVE4PjlzN{[z
NUGC3	M1zLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPOOUDPxE1?	M4PVbVI1KGh?		NV3G[2dIT0l3ME2yMlc6KM7:TR?=	M4fIWVE4QTB2OESz
CCD1059SK	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGX1OZFKSzVyPUSzMlUh\|ryP	MmK2NVgzPDd3NUS=
HepG2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\wTWM2OD1yLkCwNFYh\|ryP	M1Tk[FE5OjR5NUW0
HT1080	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fkPGlEPTB;MD6wNFI1KM7:TR?=	NVTQW5RFOTh{NEe1OVQ>
SKBR3	NV;FT5lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfPOGs1UUN3ME2wMlgh\|ryP	MnXNNVgzPDd3NUS=
SNB78	Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\0c5NDTUN3ME2xOkDPxE1?	NHzmXHgyQDJ2N{W1OC=>
SQ20B	M4i5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLvXlVKSzVyPUOg{txO	MWGxPFI1PzV3NB?=
St4	M2XPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvFR\|UxRTVwMjFOwG0>	NYPmfZh{OTh{NEe1OVQ>
MCF7	MnrTSpVv[3Srb36gRZN{[Xl?	M2jZeFExKM7:TR?=	NFnIcWk5KGh?	MVLEUXNQ	M2LGWmlv\HWldHnvckBw\iC2dXL1cIlvKGi7cHXyZYNmfHmuYYTpc44>	NWPZNoJuOTh{NkmyNlY>
HEK293	MnLhT4lv[XOnIFHzd4F6		NHnVO\|QyKGh?	MWLEUXNQ	MVvJcohq[mm2aX;uJI9nKEiGQVOxJJdqfGhiSVO1NEBw\iByLkCzJO69VQ>?	M3zCeVE5OzB6NU[z
HEK293	MUjLbY5ie2ViQYPzZZk>		NFyxOlMyKGh?	NVrY[WRwTE2VTx?=	MoTGTY5pcWKrdHnvckBw\iCKRFHDN{B4cXSqIFnDOVAhd2ZiMD6wOVch\|ryP	MoD3NVg{ODh3NkO=
G401	M2XPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWHpfFZ4PzJiaB?=	NEf5XnRFVVOR	MmjPTWM2OD1zIN88US=>	NUKxXYVkOTh\|N{CzO\|M>
HeLa	Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MX[3NkBp	M1jrUWROW09?	M1Hq[WlEPTB;MD60OkDPxE1?	MkPDNVg{PzB\|N{O=
Human renal epithelial cell	M4Lqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MljFO\|IhcA>?	M{TrSmROW09?	M1\IcWlEPTB;MUSg{txO	M{\RTlE5OzdyM{ez
U937	NIDjT2RHfW6ldHnvckBCe3OjeR?=	NGi1TlY2KM7:TR?=	NVLGVml3OjRiaB?=		NF\Q[IJKdmS3Y4Tpc44hd2ZiaHnzeI9v\SCKNDDofZBmemGlZYT5cIF1cW:w	M4npVVE5OzhzMkO4
U937	NGSyWXZHfW6ldHnvckBCe3OjeR?=	M1XaVFUh\|ryP	MlzqNlQhcA>?		NEjaXYtKdmS3Y4Tpc44hd2ZiYXzwbIEhfHWkdXzpckBpgXCncnHj[ZR6dGG2aX;u	M1zVc\|E5OzhzMkO4
U937	NFf2XHpHfW6ldHnvckBCe3OjeR?=	NHT5b5Y2KM7:TR?=	MX6yOEBp		MVrJcoR2[3Srb36gc4YheDJzIHX4dJJme3Orb36=	M4LibVE5OzhzMkO4
U937	MnTESpVv[3Srb36gRZN{[Xl?	NIjOOGk2KM7:TR?=	NHrKNo0zPCCq		MV3JcoR2[3Srb36gc4Yh[XCxcITvd4l{	NXT4doQxOTh\|OEGyN\|g>
U937	NXTGN4lmTnWwY4Tpc44hSXO\|YYm=	M1HkPVUh\|ryP	M{nw[FI1KGh?		NF\oWYlKdmS3Y4Tpc44hd2ZiZ4LhcpVtd2O7dHnjJIRq\m[ncnXueIlifGmxbh?=	M4nNVFE5OzhzMkO4
U937	MXTLbY5ie2ViQYPzZZk>	NH\FNWU2KM7:TR?=	MkDSNlQhcA>?		NGLxZmVKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVOx	NH;NTmsyQDN6MUKzPC=>
U937	NF\mWItMcW6jc3WgRZN{[Xl?	M1WxVVUh\|ryP	MnT1NlQhcA>?		NHTxN3RKdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO0	NUG4TIVnOTh\|OEGyN\|g>
HEK-TE	M1S4bWZ2dmO2aX;uJGF{e2G7	NEDrSXo2KM7:TR?=	MknWOog>	MnHESG1UVw>?	MnO5TY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCjY3X0fYxifGmxbh?=	MX[xPFQ{PDF2NB?=
HPDE6c7	NX\4VlN4S3m2b4TvfIlkKEG\|c3H5	M2fVO\|UxKM7:TR?=	NVftfnJtPzJiaB?=	MkfVSG1UVw>?	NGXG[5ZKSzVyPUGuN{DPxE1?	Ml\DNVg1QTR2NkO=
Human microvascular epithelial cell	MYXDfZRwfG:6aXOgRZN{[Xl?	MoTDOVAh\|ryP	MUm3NkBp	NVf0T2hnTE2VTx?=	MonSTWM2OD1zLkOg{txO	MVyxPFQ6PDR4Mx?=
Hup T3	NVG4RVFLS3m2b4TvfIlkKEG\|c3H5	MX21NEDPxE1?	MlL2O\|Jp	NIjSdWtFVVOR	M1jWWWlEPTB;MD64JO69VQ>?	MoLnNVg1QTR2NkO=
Mia Paca2	NF7PeoVEgXSxdH;4bYMhSXO\|YYm=	MWC1NEDPxE1?	MofUO\|Jp	M36yUGROW09?	NGTLTFFKSzVyPUGuNUDPxE1?	MVqxPFQ6PDR4Mx?=
Panc 04.03	NH;zWYREgXSxdH;4bYMhSXO\|YYm=	M3fl[\|UxKM7:TR?=	NHfNVHA4Omh?	NYniO4VUTE2VTx?=	M4HlOmlEPTB;MT6yJO69VQ>?	MUixPFQ6PDR4Mx?=
SU 86.86	M33ycmN6fG:2b4jpZ{BCe3OjeR?=	NYrYOYNLPTBizszN	MX[3Nog>	MXTEUXNQ	NYDORVhoUUN3ME2xMlMh\|ryP	NETzTnEyQDR7NES2Ny=>
HEK293	NUe1SIxHU2mwYYPlJGF{e2G7		M{PER\|MhcA>?		MX\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFjERWM3KGW6cILld5Nqd25id3n0bEBKSzVyIH;mJFAvODF7IN88US=>	NE\tepAyQDV3OE[2PS=>
HeLa	MYLLbY5ie2ViQYPzZZk>		NUfwVmZvOiCq		NH3yUFJKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh\|ryP	NV2x[5NxOTh3NUi2Olk>
RAW264.7	NInr[VVHfW6ldHnvckBCe3OjeR?=	NFHZUGEzKM7:TR?=	Ml;hN{42KGh?	MnnrSG1UVw>?	M4Gzb2FvfGmvYXzhdolidCCjY4Tpeol1gSCjZ3HpcpN1KFCuYYPtc4RqfW1iZnHsZ4lx[XK3bTDpcoZm[3SnZDD3bZRpKEmFNUCgc4YhOC5zMTFOwG0>	NYfUUIJMOTh4NES5Olk>
NB4			M2fTblQ5cA>?	Mmq2SG1UVw>?	M3TC[mlEPTB;MD62JO69VQ>?	MkPNNVg4OjN\|NEm=
HEK293	MmDISpVv[3Srb36gRZN{[Xl?	MVuxNEDPxE1?	NF61dW8zPCCq	MlXlSG1UVw>?	NI[zWmZC[3SrdnH0bY9vKG:oIH3veZNmKFewdEPhJJNq\26jbHnu[{BmgHC{ZYPz[YQ>	MVmxPVAzOjZ5NR?=
HCT116	NHLHU3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVq3Nog>	MWLEUXNQ	MkP1TWM2OD1yLkOxJO69VQ>?	MYGxPVA5PDJ7NB?=
HeLa	M1jLeWtqdmG\|ZTDBd5NigQ>?	MX:yJO69VQ>?	MVmzNEBucW5?	MlWwSG1UVw>?	M4qy[mlvcGmkaYTpc44hd2ZiSFTBR\|IhcW5iaIXtZY4hUGWOYTDj[YxteyC5aYToJGlEPTBib3[gNE4yKM7:TR?=	NInVboIyQTB6NEK5OC=>
IGROV1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mm\qO\|IhcA>?	NYLleop6TE2VTx?=	MmXpTWM2OD1{LkKg{txO	NWrVWIxwOTlyOESyPVQ>
IGROV1	M{HHOWtqdmG\|ZTDBd5NigQ>?	MljpOUDPxE1?	NVOxdGNJOjRiaB?=	M{HLbmROW09?	MmrOTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=>	NFjjbVgyQTB6NEK5OC=>
IGROV1	MkHoT4lv[XOnIFHzd4F6	NXrOZo9tOTBizszN	Mke5OEBp	NXjtc3hDTE2VTx?=	MWXJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[U1JPCCjY3X0fYxifGmxbh?=	MonBNVkxQDR{OUS=
IGROV1	MVLLbY5ie2ViQYPzZZk>	NY\5PVJwOTBizszN	NXrD[FRIPCCq	M{Dh[2ROW09?	NFy0UZpKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHsdIhiNXS3YoXsbY4h[WOndInsZZRqd25?	MnjpNVkxQDR{OUS=
T24	MVLLbY5ie2ViQYPzZZk>		NHjyfZc{KGh?		MljaTY5lfWO2aX;uJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMUKg{txO	M4HFOlE6ODh2M{m1
T24	MlfvT4lv[XOnIFHzd4F6		NF\Pcnc{KGh?		MnLQTY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNlUh\|ryP	MVmxPVA5PDN7NR?=
HeLa	M2XpNWtqdmG\|ZTDBd5NigQ>?		MV6xOUBucW5?	NXfTWGcyTE2VTx?=	M2W1T2lvcGmkaYTpc44hd2ZiSFTBR\|Yh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFAvODh3NTFOwG0>	NYPEd3ZqOTlyOUO4PFQ>
HeLa	NF;RN5FMcW6jc3WgRZN{[Xl?		NWfPeYVHOTVibXnu	NFHDOYFFVVOR	M1\3SWlvcGmkaYTpc44hd2ZiSFTBR\|gh\nKxbTDueYNt\WG{IHX4eJJi[3Rid3n0bEBKSzVyIH;mJFEvQDZizszN	NHL5PWIyQTB7M{i4OC=>
NCI-H69	M1vneGN6fG:2b4jpZ{BCe3OjeR?=		M1LI[FczKGh?	NEfNfW9FVVOR	NEjx[mZKSzVyPUKuNFYh\|ryP	MWKxPVA6Ozh6NB?=
SKMES1	NEXlU3dEgXSxdH;4bYMhSXO\|YYm=		M2LxdFczKGh?	MVLEUXNQ	NFfJdldKSzVyPUKuOFIh\|ryP	M{T2WFE6ODl\|OEi0
S2	MUHLbY5ie2ViQYPzZZk>	M13HNVAvOS1zMDFOwG0>	M3ftdVEhcA>?		M4TlNmlvcGmkaYTpc44hd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGhFSUNzIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yNUmg{txO	NVTXTWFMOTl\|MUe0OVA>
SHSY5Y	Mki1T4lv[XOnIFHzd4F6	M4\Y[\|ExKM7:TR?=	M1fG[lQ5KGh?	NY\qNpdLTE2VTx?=	NYjR[oo5UW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlUh\|ryP	M3\SXVE6OzR2MUe1
SHSY5Y	MljDR5l1d3SxeHnjJGF{e2G7	NEXJeoUyOCEQvF2=	M4ru[\|Q5KGh?	M1jHNmROW09?	M1rvWWlEPTB;MjFOwG0>	M37zR\|E6OzR2MUe1
DMS114	NF3kdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGfnfoY1QCCq		NYTESnF[T0l3ME2yMlkh\|ryP	NVvBNo1FOTl2MUmyNFU>
HBC5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3jVfFQ5KGh?		M1LYcWdKPTB;MUeg{txO	M4DLe\|E6PDF7MkC1
SNB78	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1nORVQ5KGh?		NF\hZYRIUTVyPUG2JO69VQ>?	Mnv6NVk1OTl{MEW=
HeLa	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mnf0O\|IhcA>?	MWjEUXNQ	M1vkeWlEPTB;MD60OkDPxE1?	NEfhdWsyQTR2MUi0Oi=>
BHK	NGDWenBMcW6jc3WgRZN{[Xl?	NGHqOVE2KM7:TR?=	M2Hx[\|I1KGh?	NYLIVJFZTE2VTx?=	M{TCU2lvcGmkaYTpc44hd2ZiSFTBR\|ch\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJBt[XOvYTDt[Y1jemGwZTDG[IVtfGF3MEigR2ZVWiCycn;0[Ylv	M3XS[FE6QTZ4N{i5
CFBE41o-	NYixfGNLU2mwYYPlJGF{e2G7	MW[1JO69VQ>?	NXnHb3E5QCCq	M3TVbWROW09?	NXTUboRnUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHj5dIVz[WOndInsZZRqd25ib3[gbIl{fG:wZTDINy=>	NYfJc3BJOTl7Nk[3PFk>
CFBE41o-	NV7a[JpFU2mwYYPlJGF{e2G7	NEHLNIg2KM7:TR?=	NHLZ[IQ1KGh?	Mn;TSG1UVw>?	NYXiemZVUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGyndnXs	MlHXNVk6PjZ5OEm=
CFBE41o-	NG[1cmFMcW6jc3WgRZN{[Xl?	MUOxJO69VQ>?	NFrsOpAyKGh?	NV;r[GtoTE2VTx?=	NXzWTVByUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGNHXFJicILveIVqdiCuZY\lcC=>	NYHzfVU4OTl7Nk[3PFk>
Primary bronchial epithelial cell	M1zBc2tqdmG\|ZTDBd5NigQ>?	MmDENUDPxE1?	NFPRcmczPCCq	M{S1XGROW09?	NGr6SpJKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	Mn7HNVk6PjZ5OEm=
CFBE41o-	NFPBcllMcW6jc3WgRZN{[Xl?	M2rvd\|Eh\|ryP	M4XRclUh\GG7cx?=	MX7EUXNQ	NFT1fWRKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn6ZZRqd25ib3[gSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	NILQdGgyQTl4Nke4PS=>
CFBE41o-	MUXLbY5ie2ViQYPzZZk>	M4[5S\|Eh\|ryP	MnLONlQhcA>?	M{mzRmROW09?	NIXVSlBKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5idILh[oZq[2urbne=	MmnTNVk6PjZ5OEm=
CFBE41o-	M1;RXGtqdmG\|ZTDBd5NigQ>?	NVvqWpVbPSEQvF2=	MYqyOEBp	M3nrS2ROW09?	NXrPc3dnUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBz[XSnIH;mJI1ifHW{YYTpc44hd2ZiQ1\UVkBxem:2ZXnuJJRwKGm2czDncJlkd2[xcn2=	M4W0OFE6QTZ4N{i5
CFBE41o-	M4W2bWtqdmG\|ZTDBd5NigQ>?	NELTNY42KM7:TR?=	M{LlVVI1KGh?	MnLJSG1UVw>?	Mnj5TY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDzeIFjcWyrdImgc4YhTmSnbIThOVA5KEOIVGKgdJJwfGWrbh?=	MVixPVk3Pjd6OR?=
CFBE41o-	MWjLbY5ie2ViQYPzZZk>	NUjieYtnPSEQvF2=	NXT6boYzOjRiaB?=	M{i0SWROW09?	M1LRPGlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiY3;ydoVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJidILh[oZq[2urbnegeI8h[2WubDDzeZJn[WOnIHHzJIdtgWOxZn;ycS=>	MmKxNVk6PjZ5OEm=
Primary bronchial epithelial cell	NV7QO45KU2mwYYPlJGF{e2G7	MlPWOUDPxE1?	NUP1T2lEOjRiaB?=	NU\HXWd5TE2VTx?=	NIX2U4JKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	MlTINVk6PjZ5OEm=
Primary bronchial epithelial cell	NFTqcVdMcW6jc3WgRZN{[Xl?	M1:4clEh\|ryP	NEfXNGs6PiCq	MVnEUXNQ	NXPkVIczUW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS\|	MX6xPVk3Pjd6OR?=
BxPC3	NXjZbJRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWi1WFBjPzJiaB?=		MW\JR\|UxRTJwNzFOwG0>	M1jQdlIxOTR\|N{e4
CAL27	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[3NkBp		NX;UfXc4UUN3ME2zMlczKM7:TR?=	NXXTNlhVOjBzNEO3O\|g>
Capan1	MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkfXO\|IhcA>?		M1;2SWlEPTB;Nz6zJO69VQ>?	Mk\6NlAyPDN5N{i=
HCC827	MmDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXW3NkBp		M3voc2lEPTB;MT64JO69VQ>?	Mlj2NlAyPDN5N{i=
LNCAP	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{nxflczKGh?		MoPwTWM2OD1yLkW4JO69VQ>?	NGHUdG0zODF2M{e3PC=>
NCI-H2122	NE\Zd\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NX;3b3QzPzJiaB?=		MlHlTWM2OD15LkWg{txO	MY[yNFE1Ozd5OB?=
NCI-H358	NY[5[5U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYG3NkBp		M4LIVmlEPTB;Mj61JO69VQ>?	MkftNlAyPDN5N{i=
SCC15	MoTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{jpWlczKGh?		MmXjTWM2OD1{LkS5JO69VQ>?	NVrETHV5OjBzNEO3O\|g>
SCC25	M2jIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MlXIO\|IhcA>?		MlXhTWM2OD1zLkmzJO69VQ>?	M37SVFIxOTR\|N{e4
SKHEP1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVH1WIJNPzJiaB?=		MVzJR\|UxRTNwNE[g{txO	M3nv[VIxOTR\|N{e4
BJ	NX34WHo{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrZRVNpOTByIN88US=>	NIruVIM1QCCq	MVrEUXNQ	M4[1eGdzd3e2aDDpcohq[mm2aX;uJIF1KDBwMEWgeI8hOTByIIXN	NVH6UXh3OjBzNEO4OFA>
MUF	M2DWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7DbZEyODBizszN	MlXvOFghcA>?	MknWSG1UVw>?	NHfyXWtIem:5dHigbY5pcWKrdHnvckBifCByLkC1JJRwKDFyMDD1US=>	MoLJNlAyPDN6NEC=
Caco-2	MnPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjHNVAxKM7:TR?=	NVPWO4tTPDiq	NGTMb45FVVOR	Ml7RTWM2OD16LkGg{txO	MnrwNlAyPDN6NEC=
Caco-2	M1r3bmtqdmG\|ZTDBd5NigQ>?	M2DUS\|Uh\|ryP	MU[0JIg>	Mo\JSG1UVw>?	MVrJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;uJGlEPTBib3[gNE4xOzdizszN	NUe0c\|U{OjBzNEO4OFA>
Caco-2	MnP2T4lv[XOnIFHzd4F6	MXiwMlMyPiCwTTD0c{A{OS54IN88US=>	MoWxOEBp	MUjEUXNQ	M4\tR2V5KH[rdn:gbY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMTD3bZRpKEmFNUCgc4YhOC5zMUmg{txO	NX\BU3dOOjBzNEO4OFA>
Caco-2	Mkn4T4lv[XOnIFHzd4F6	NGDENY0xNjNzNjDuUUB1dyB\|MT62JO69VQ>?	M3fw[VQhcA>?	Mlv2SG1UVw>?	NFzFRnVGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Oge4l1cCCLQ{WwJI9nKDBwMUS3JO69VQ>?	MnPxNlAyPDN6NEC=
Caco-2	NIq0eVhMcW6jc3WgRZN{[Xl?	NW[xWWdSPi5\|MjDuUUB1dyB4M{Kg{txO	MVO0JIg>	Mn;hSG1UVw>?	NWDmZoloTXhidnn2c{BqdmirYnn0bY9vKG:oIHj1cYFvKEiGQVO1JJdqfGhiSVO1NEBw\iBzMj62JO69VQ>?	NEXDW4gzODF2M{i0NC=>
Caco-2	NXnGd2ZrU2mwYYPlJGF{e2G7	NIfrR\|c3NjN{IH7NJJRwKDZ\|MjFOwG0>	MV[0JIg>	MWLEUXNQ	MmrRSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2=	MUeyNFE1Ozh2MB?=
Caco-2	MXTLbY5ie2ViQYPzZZk>	M1TS[VAvOzF4IH7NJJRwKDNzLk[g{txO	M1m4N\|QhcA>?	NV;NfYlmTE2VTx?=	MWPFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ?	NHvrNZEzODF2M{i0NC=>
HepG2	NH\DdlZMcW6jc3WgRZN{[Xl?	M3G1fVUh\|ryP	NHL5cG83cA>?	MnLVSG1UVw>?	NEnpXIpKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBpcXO2b37lJIFk\XS7bHH0bY9v	Ml[zNlAyPDN6NEC=
HepG2	NWHsTIZrU2mwYYPlJGF{e2G7	M17PVVUh\|ryP	NGfvUoc3cA>?	MYDEUXNQ	MYnJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHj5dIVz[WOndInsZZRqd25?	MYSyNFE1Ozh2MB?=
HepG2	NXjRe4F6U2mwYYPlJGF{e2G7	NH3HOYc2KM7:TR?=	NVLTfFNSPmh?	NVjucYZETE2VTx?=	MYrJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	NHzGPZozODF2M{i0NC=>
HepG2	MmjYT4lv[XOnIFHzd4F6	NVvFT2xpPSEQvF2=	NFrFZY43cA>?	MUXEUXNQ	NF7we4ZKdmS3Y4Tpc44hd2ZiSFTBR{1u\WSrYYTl[EBJOy:KNDDobZN1d26nIHHj[ZR6dGG2aX;u	M{jBd\|IxOTR\|OESw
COLO205	NGDHN\|RMcW6jc3WgRZN{[Xl?	MUixNEDPxE1?	MVOyOEBp	M2O4VGROW09?	NIWxNlJKdmirYnn0bY9vKG:oIFjERWMyKGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBpcXO2b37lJGg{KGGlZYT5cIF1cW:wIIfpeIghUUN3MDDv[kAzNjJizszN	NXrDO\|BzOjB2NUGzO\|g>
SCC4	NIjO[mNMcW6jc3WgRZN{[Xl?	Mn74NUDPxE1?	MUWyOIg>		NFz0dpBKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6geJVjfWyrbjDhZ4V1gWyjdHnvci=>	Mn3MNlA1PTJ{MkW=
SCC4	NXTteFdbU2mwYYPlJGF{e2G7	NVHybJpFOSEQvF2=	M3S2UFI1cA>?		M2jnWWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIHHj[ZR6dGG2aX;u	NEPo[JQzODR3MkKyOS=>
SCC4	MnP6SpVv[3Srb36gRZN{[Xl?	NFfMfmUyKM7:TR?=	M1\jR\|UhdWmw		MV\B[49vcXO2IHHjeIl3cXS7IHH0JHZFWiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhS1mSMkSg[4Vv\SCneIDy[ZN{cW:w	MV[yNFQ2OjJ{NR?=
NB4	MYTGeY5kfGmxbjDBd5NigQ>?	NGSxb4M2KM7:TR?=	M1\zN\|I1KGh?	MVHEUXNQ	NHi1NW9E\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDhZ4N2dXWuYYTpc44h[XRicILlMWcyKHCqYYPl	NE\6UYwzODR7MUS0NC=>
NB4	NFj0[2FMcW6jc3WgRZN{[Xl?	NHu1VJg2KM7:TR?=	NH7CbY8zPCCq	MnrpSG1UVw>?	NW\Db2FCUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIFk\XS7bHH0[UB1fWK3bHnuJIxmfmWu	MoLWNlA1QTF2NEC=
NB4	MWHGeY5kfGmxbjDBd5NigQ>?	NWGw[IJuPSEQvF2=	M3XlV\|I1KGh?	M2\QXWROW09?	MlPMTY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;u	Ml:1NlA1QTF2NEC=
NB4	M4TKeWtqdmG\|ZTDBd5NigQ>?	MVi1JO69VQ>?	MX:yOEBp	MWfEUXNQ	MnnDTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSEOgZYNmfHmuYYTpc44>	NYK5WXhkOjB2OUG0OFA>
NUGC3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\GPHFIUTVyPUKuPVQh\|ryP	M4TQS\|IxQDVyOUex
A549	MlnpSpVv[3Srb36gRZN{[Xl?	M{[zXlUh\|ryP	M3\nUlMhcA>?	M2rYT2ROW09?	MknnTY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	NIXNUHYzODh3NUKwPC=>
HUT78	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUizWYhwPzJiaB?=	NGj3TWdFVVOR	NIewWVdIUTVyPUCuN{DPxE1?	NYe4fm02OjB6OESyNFg>
U937	NF[4[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MWe3NkBp	M1LnbWROW09?	NUPyPGZIT0l3ME2wMlM6KM7:TR?=	NUL0N2p5OjB6OESyNFg>
A431	M2Sx[GN6fG:2b4jpZ{BCe3OjeR?=		M17rbFczKGh?		Ml;NR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKHerdHigTWM2OCCxZjC0MlIh\|ryP	M1\QRVIyODhyNkK5
A549	M3GzdWN6fG:2b4jpZ{BCe3OjeR?=		NU\jNXFnPzJiaB?=		MnjJR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlgh\|ryP	NVXTTZJqOjFyOEC2Nlk>
CAL27	M2LBdWN6fG:2b4jpZ{BCe3OjeR?=		NYLKeIRIPzJiaB?=		NFjN[4hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBESUx{NzDj[YxteyCxdnXy[ZhxemW\|c3nu[{BGT0[UIIfpeIghUUN3MDDv[kA{NjJizszN	Mom1NlExQDB4Mkm=
HeLa	NXP6V5E5S3m2b4TvfIlkKEG\|c3H5		MXO3NkBp		MofqR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{BwfmW{ZYjwdoV{e2mwZzDISGFEKHerdHigTWM2OCCxZjCxMlUh\|ryP	NUS4OGZEOjFyOEC2Nlk>
Sf21	M{\lW2tqdmG\|ZTDBd5NigQ>?		NGfqc5A{KGh?		MYDJcohq[mm2aX;uJI9nKE[uYXegeIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IFjERWM5KGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4zKM7:TR?=	NUfXV3ZzOjFyOEC2Nlk>
SKBR3	MWjDfZRwfG:6aXOgRZN{[Xl?		M{\J[\|czKGh?		M4jDPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvPiEQvF2=	MUmyNVA5ODZ{OR?=
SKOV3	NYjQWIEyS3m2b4TvfIlkKEG\|c3H5		NFPjeVM4OiCq		M3;Nd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMV1Z\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvOiEQvF2=	NXLTN4plOjFyOEC2Nlk>
COR-L23	NEnEeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfMZYUyOCEQvF2=	NY[xNlY{PzJiaB?=	M{T0XmROW09?	NYe1ZWdpT0l3ME2xMlEh\|ryP	NXy3N4pUOjFyOEC2OFc>
DU145	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzafncyOCEQvF2=	NHTKeFc4OiCq	NUTDNIc5TE2VTx?=	Ml\2S2k2OD1zLkC1JO69VQ>?	NYHKVpVrOjFyOEC2OFc>
LoVo	NXjme242T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWfNT2puOTBizszN	NE\yeno4OiCq	MWTEUXNQ	NV\rN2NkT0l3ME2xMlch\|ryP	NH3Udm0zOTB6ME[0Oy=>
MCR5-SV2	NVrjR2kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVH0b2ZSOTBizszN	NIrTcJM4OiCq	NVe0dHZOTE2VTx?=	MVvHTVUxRTJwMTFOwG0>	NUTER5d4OjFyOEC2OFc>
HCT116	NFjwdm5McW6jc3WgRZN{[Xl?	NIXJdmc{OCEQvF2=	M3q3dVMxKGh?	NFe3SJpFVVOR	NH7Od41KdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBidHCqYT30eYJ2dGmwIHHj[ZR6dGG2aX;u	Mn:1NlExQDB4NEe=
HCT116	M{TabGtqdmG\|ZTDBd5NigQ>?	MluwN\|Ah\|ryP	MnH5N\|AhcA>?	Ml7kSG1UVw>?	NYjpb4ZkUW6qaXLpeIlwdiCxZjDISGFEOSCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4YhcGm\|dH;u[UBJO0t7IHHj[ZR6dGG2aX;u	MmK5NlExQDB4NEe=
U937	MmnMT4lv[XOnIFHzd4F6	NXfsXopnPSEQvF2=	M1\OUlI1KGh?	MleySG1UVw>?	NUn4XXZJUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{m=	MmroNlEzQTJ2OUK=
U937	NUK0S2ZJU2mwYYPlJGF{e2G7	M2S1c\|Uh\|ryP	MX2yOEBp	M1HJS2ROW09?	NFz1eFlKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4Yh[WOndInsZZRqd25ib3[gbIl{fG:wZTDIN{BifCCNMUi=	NHLQWGIzOTJ7MkS5Ni=>
U937	MYDLbY5ie2ViQYPzZZk>	NHHsOHY2KM7:TR?=	NFe0WmgzPCCq	MmPmSG1UVw>?	MV7Jcohq[mm2aX;uJI9nKGirc4TvcoUh[WOndInseJJidnOoZYLhd4Uh[XO\|ZYPz[YQh[XNiaX7jdoVie2Vib3[gdIFvNWGlZYT5cIF1\WRiaHnzeI9v\SCKNDDs[ZZmdA>?	M1XrfFIyOjl{NEmy
U937	NI\kfZRMcW6jc3WgRZN{[Xl?	NVj5RnBbPSEQvF2=	Mk\mNVUhdWmw	NUHQfZNpTE2VTx?=	NWPKbph4UW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36gcIV3\Wx?	NELLUWQzOTJ7MkS5Ni=>
A2780	NYXtZodkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXe5OkBp	MWfEUXNQ	NE\XU5NKSzVyPUGuOlIh\|ryP	MUmyNVY{PDR\|MB?=
COLO205	M4XvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3LJNlk3KGh?	MlHZSG1UVw>?	MonyTWM2OD1{LkGyJO69VQ>?	MoXlNlE3OzR2M{C=
Hep3B	M2\jTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkK5OFghcA>?	NU\ROZhMTE2VTx?=	Ml7US2k2OD1zLkKxJO69VQ>?	NWTvSGEzOjF5MUKxOFY>
GM11272	MYHGeY5kfGmxbjDBd5NigQ>?	NITsd2MyODBibl2=	NEPKbZk4OiCq	NIT4ToZFVVOR	M3uwUXJm[WO2aY\heIlwdiCxZjDN[WNxOiCvdYThcpQh\XiycnXzd4lwdiCjdDCxNEB1dyBzMECgcm0>	NVzlUGt3OjF6NEC3NVY>
CFBE41o	NGC2OFNMcW6jc3WgRZN{[Xl?	MV61JO69VQ>?		M4O2XmROW09?	MmnYSI94diC{ZXf1cIF1cW:wIH;mJGhFSUN5IHH0JFAvOiC2bzC1JJVO	M1nu[lIyQTh2OUW4
CFBE41o	MVLGeY5kfGmxbjDBd5NigQ>?	MUexJO69VQ>?	NHTJVIozPCCq	M3nIcGROW09?	NV3EdnhxWmW\|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z	Ml3XNlE6QDR7NUi=
DU145	M4DWZ2tqdmG\|ZTDBd5NigQ>?	M1;VNVIvPSEQvF2=	NHS1SoEzPCCq	NEOzfnFFVVOR	NW\XUpBJUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IIXwdoVofWyjdHnvckBw\iCyMkH3ZYYyKHC{b4TlbY4h\XiycnXzd4lwdg>?	NHjrd4ozOjJ4MEG2Oi=>
DU145	MYPLbY5ie2ViQYPzZZk>	NWDDS2ZxPSEQvF2=	MXKyOEBp	NVXkN49oTE2VTx?=	M2G0V2lvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqaYP0c45mKEh2IHHj[ZR6dGG2aX;u	M1r4c\|IzOjZyMU[2
DU145	NUWzeZN{U2mwYYPlJGF{e2G7	MUO1JO69VQ>?	M1\w[VI1KGh?	NUiwRnptTE2VTx?=	NUfo[XJGUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHjpd5RwdmViSEOgbJlx\XKjY3X0fYxifGmxbh?=	NWLkXI1LOjJ{NkCxOlY>
786-0	NUOzSHpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDjRnB1Pi5{IN88US=>	MmryO\|IhcA>?	NFL1SldFVVOR	NI\mc2tIUTVyPUOuNkDPxE1?	NInCemUzOjR\|NU[2PS=>
A498	NXjlNWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrUdmpbPi5{IN88US=>	MnrmO\|IhcA>?	NFzJZoZFVVOR	NULpcW9XT0l3ME2xMlYh\|ryP	M3XBbFIzPDN3Nk[5
A549/ATCC	Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWX6cGpvPi5{IN88US=>	M4LXfFczKGh?	NInmRW1FVVOR	M2TuNmdKPTB;MT62JO69VQ>?	NXjjTVNpOjJ2M{W2Olk>
ACHN	M2K3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;XOk4zKM7:TR?=	MV23NkBp	MWLEUXNQ	NWP1RY92T0l3ME2xMlMh\|ryP	MmnaNlI1OzV4Nkm=
BT549	M1zuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnnXnE3NjJizszN	M3TyTlczKGh?	M1LuUWROW09?	M2rkRmdKPTB;MT6zJO69VQ>?	M37nblIzPDN3Nk[5
EKVX	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2r1TFYvOiEQvF2=	MnjyO\|IhcA>?	M2nrdWROW09?	MnKzS2k2OD1zLkOg{txO	NYLscW9{OjJ2M{W2Olk>
HCT15	NX\NOmQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTwOk4zKM7:TR?=	NYe1W3dqPzJiaB?=	NYXEVWU4TE2VTx?=	Ml;zS2k2OD1{LkWg{txO	M{HBT\|IzPDN3Nk[5
HOP92	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P0[FYvOiEQvF2=	NX7PdXBwPzJiaB?=	NFjhWI9FVVOR	MlLvS2k2OD12IN88US=>	MmLRNlI1OzV4Nkm=
IGROV1	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nGeFYvOiEQvF2=	NXnEc3ZHPzJiaB?=	MnHHSG1UVw>?	NUPHNph6T0l3ME2xMlMh\|ryP	MV:yNlQ{PTZ4OR?=
LOXIMVI	NWe5fW9[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWm2MlIh\|ryP	M365dlczKGh?	MY\EUXNQ	MmHJS2k2OD1zIN88US=>	NWfXXmh6OjJ2M{W2Olk>
M14	NFvOWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWK2MlIh\|ryP	NVLSd2JXPzJiaB?=	NYfQUo1qTE2VTx?=	M1zjZmdKPTB;MT6zJO69VQ>?	Mn;aNlI1OzV4Nkm=
MALME-3M	MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWS2MlIh\|ryP	MkOxO\|IhcA>?	NIj2NW5FVVOR	M1rKXWdKPTB;MD6zNkDPxE1?	NInw[5MzOjR\|NU[2PS=>
MCF10A	MnfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPhSnc3NjJizszN	M1LORVQ5KGh?	MVLEUXNQ	NILsfXhIUTVyPUmuOkDPxE1?	NYfSPZluOjJ2M{W2Olk>
MDA-MB-435	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX4Ok4zKM7:TR?=	NGP1cHY4OiCq	Mmn6SG1UVw>?	NUTESGlET0l3ME2wMlUh\|ryP	NH7VcmczOjR\|NU[2PS=>
MDA-MB-468	M3PFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUi2MlIh\|ryP	NESyW3Q4OiCq	NYHOWnBjTE2VTx?=	NUTRZm5kT0l3ME2wMlY{KM7:TR?=	MnrRNlI1OzV4Nkm=
MOLT4	NGLSOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rDeVYvOiEQvF2=	NYn3W41CPzJiaB?=	NFrGPYZFVVOR	MVHHTVUxRTBwNDFOwG0>	MkSzNlI1OzV4Nkm=
NCI-ADR-RES	NWPQe\|Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3pOk4zKM7:TR?=	M2i0SVczKGh?	M4LmVmROW09?	NHH2cVlIUTVyPUCuNVYh\|ryP	Mmr0NlI1OzV4Nkm=
NCI-H23	M1\WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1joZlYvOiEQvF2=	NILiSY84OiCq	NI\a[FJFVVOR	M3PWbmdKPTB;MTFOwG0>	NVzJPHFNOjJ2M{W2Olk>
NCI-H322M	M1T5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFG5SFQ3NjJizszN	MUW3NkBp	Ml\BSG1UVw>?	NUjPTFZnT0l3ME2wMlc6KM7:TR?=	MkGwNlI1OzV4Nkm=
NCI-H460	NEe2boFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MneyOk4zKM7:TR?=	NIfiZ5k4OiCq	MWXEUXNQ	MlW3S2k2OD1yLke5JO69VQ>?	NFTUdIEzOjR\|NU[2PS=>
NCI-H522	MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH33TII3NjJizszN	NIjMSW04OiCq	MlnHSG1UVw>?	NV3MeJBmT0l3ME2wMlUh\|ryP	M1vBOFIzPDN3Nk[5
OVCAR3	NVHvcnlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXpOk4zKM7:TR?=	NHq5ToQ4OiCq	NVLOeo9YTE2VTx?=	NYjtOlUyT0l3ME2xMlMh\|ryP	NXfhR\|RDOjJ2M{W2Olk>
OVCAR4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fO[lYvOiEQvF2=	NV;jNHl2PzJiaB?=	M33sbmROW09?	M3XMWGdKPTB;NDFOwG0>	NXLT[WNUOjJ2M{W2Olk>
OVCAR5	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWi2MlIh\|ryP	NFrNbGE4OiCq	MmLCSG1UVw>?	M1i0eGdKPTB;MD63PUDPxE1?	Mmj1NlI1OzV4Nkm=
OVCAR8	M2fm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHEVoxYPi5{IN88US=>	NEKwe244OiCq	MmHQSG1UVw>?	M3jyN2dKPTB;MD61JO69VQ>?	NIi4RVMzOjR\|NU[2PS=>
RXF393	NGqzb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHTbIY3NjJizszN	NITadVQ4OiCq	NGTGS45FVVOR	MVzHTVUxRTFwMzFOwG0>	MYKyNlQ{PTZ4OR?=
SF268	NFLUTohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlT5Ok4zKM7:TR?=	MVO3NkBp	NUfYRWpkTE2VTx?=	NEXIcZhIUTVyPUGuOkDPxE1?	MlfuNlI1OzV4Nkm=
SF295	NGTEUYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjEeFRqPi5{IN88US=>	NXTGdJdlPzJiaB?=	M33nXGROW09?	Mnj0S2k2OD1zLk[g{txO	MWmyNlQ{PTZ4OR?=
SF539	NYTjUZN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13qZlYvOiEQvF2=	MX:3NkBp	MVPEUXNQ	M1;KdmdKPTB;MjFOwG0>	MYKyNlQ{PTZ4OR?=
SK-MEL-2	M3nMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWK2MlIh\|ryP	M4DCUVczKGh?	MVfEUXNQ	MoL6S2k2OD1zLkOg{txO	MVqyNlQ{PTZ4OR?=
SK-MEL-28	NGnCNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrNOk4zKM7:TR?=	M{nDbVczKGh?	MYHEUXNQ	MUfHTVUxRTFizszN	NW[2Uo5TOjJ2M{W2Olk>
SK-MEL-5	NUTQWFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjiOk4zKM7:TR?=	MYO3NkBp	MXXEUXNQ	NGn0XVZIUTVyPUCuOlMh\|ryP	NHzCPFAzOjR\|NU[2PS=>
SKOV3	MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXWe4xYPi5{IN88US=>	MnXxO\|IhcA>?	NI\we4RFVVOR	MUfHTVUxRTFizszN	NIHrT28zOjR\|NU[2PS=>
SN12C	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TudFYvOiEQvF2=	MXS3NkBp	M2\5TmROW09?	NVHwUYdkT0l3ME2yJO69VQ>?	MVmyNlQ{PTZ4OR?=
SNB19	NX3lVWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\tOk4zKM7:TR?=	MXy3NkBp	NEDRUHdFVVOR	MmPsS2k2OD1yLk[zJO69VQ>?	M1HpSlIzPDN3Nk[5
SNB75	M{e1e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLFNXY3NjJizszN	NUnnXVFkPzJiaB?=	Mnj2SG1UVw>?	NFvEUmlIUTVyPUCuO\|kh\|ryP	MnjwNlI1OzV4Nkm=
SR	NFnTXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnCOk4zKM7:TR?=	MXW3NkBp	NYPYN2ZjTE2VTx?=	MWDHTVUxRTBwNDFOwG0>	MXqyNlQ{PTZ4OR?=
T47D	NITWXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfqc283NjJizszN	Mk[3O\|IhcA>?	M1\Nb2ROW09?	MknlS2k2OD1yLkWg{txO	NFm2XWYzOjR\|NU[2PS=>
TK10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmThOk4zKM7:TR?=	MWq3NkBp	Mn7BSG1UVw>?	MYLHTVUxRTBwNkOg{txO	M3\ZSFIzPDN3Nk[5
UACC257	NVvQR4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnqbppoPi5{IN88US=>	MlnmO\|IhcA>?	MmrFSG1UVw>?	MWHHTVUxRTBwNTFOwG0>	M{\1WlIzPDN3Nk[5
UACC62	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nmO\|YvOiEQvF2=	MVm3NkBp	M1ztO2ROW09?	MVjHTVUxRTBwNDFOwG0>	MU[yNlQ{PTZ4OR?=
UO31	NYPSUXYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjLS5c3NjJizszN	NHHlNnk4OiCq	MUHEUXNQ	MoW0S2k2OD1yLkWg{txO	NXP1[JM2OjJ2M{W2Olk>
Hep3B	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{P3Z\|Q5KGh?	NXTofGgxTE2VTx?=	MnfHS2k2OD1yLk[5JO69VQ>?	MVeyNlQ{QTh4Mx?=
BE(2)-C	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2SzPVczKGh?	MlH2SG1UVw>?	MWjJR\|cxRTJizszN	NFjC[JQzOjl\|MkOxOi=>
Bel7402	NVy1UZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV[zW2ltPzJiaB?=	Mo\aSG1UVw>?	NFPiNXlIUTlyPUG3JO69VQ>?	NYLLc4M3OjNyNkGzO\|Y>
Bel7404	M33rbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWnqS215PzJiaB?=	NFXPOG1FVVOR	NFrkSplIUTlyPUG4JO69VQ>?	MknONlMxPjF\|N{[=
BGC823	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkXaO\|IhcA>?	NVHYV2lkTE2VTx?=	NUjXV4FqT0l7ME23MlUh\|ryP	M{TSdVI{ODZzM{e2
MGC803	MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NFXwOZk4OiCq	M2e4UmROW09?	MYfHTVkxRTFyLkig{txO	NHnLTZozOzB4MUO3Oi=>
SGC7901	NHPNZ2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVu3NkBp	MoCwSG1UVw>?	NYXWR2V[T0l7ME25MlQh\|ryP	M{TqVVI{ODZzM{e2
SKHEP1	NX;a[2xST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MYK3NkBp	MlXrSG1UVw>?	MmqyS2k6OD1zNzFOwG0>	NVv3Nm9HOjNyNkGzO\|Y>
SMMC7721	NFnqSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWm2[2h4PzJiaB?=	NG\0fnFFVVOR	NFTC[ZlIUTlyPUKwJO69VQ>?	M3L2OlI{ODZzM{e2
NUGC3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYexNEDPxE1?			NUDVO\|dsT0l;Mj65OEDPxE1?	M1mxTlI{OTZ\|M{Oy
A2780 CisR	M2XsV2tqdmG\|ZTDBd5NigQ>?		NXfs[Gc1OThiaB?=		NEjmbGdKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuOFQh\|ryP	M3LDSlI{OjV{NkCz
CAL27 sens	NXLveWx7U2mwYYPlJGF{e2G7		MWixPEBp		NG[zbHVKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuN\|Yh\|ryP	NYfKc5JmOjN{NUK2NFM>
CAL27 CisR	NIDkXWtMcW6jc3WgRZN{[Xl?		MV:xPEBp		Mn\RTY5pcWKrdHnvckBw\iCKRFHDJJdqfGhiSVO1NEBw\iByLk[xJO69VQ>?	NXzQO5pKOjN{NUK2NFM>
KYSE-510 CisR	NYPNTJJrU2mwYYPlJGF{e2G7		NEXne5YyQCCq		M1TWcmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD61PUDPxE1?	M4jJ[FI{OjV{NkCz
KYSE-510 sens	NYLaTnlZU2mwYYPlJGF{e2G7		NYrQUZhDOThiaB?=		NF7L[GRKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuO{DPxE1?	MUmyN\|I2OjZyMx?=
MDA-MB-231 sens	MlzpT4lv[XOnIFHzd4F6		NGHEdnAyQCCq		M3i4bGlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	MUmyN\|I2OjZyMx?=
MDA-MB-231 CisR	MX3LbY5ie2ViQYPzZZk>		M3P3NlE5KGh?		M3\UZmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	NUXzWosxOjN{NUK2NFM>
ES2	NYTWR\|g6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MV60PEBp	NXK5XIZVTE2VTx?=	NIjNfIpKSzVyPUGyMlch\|ryP	NFnvfXczOzR7M{S0PS=>
MDA-MB-231	NFXEem1McW6jc3WgRZN{[Xl?	MYWxNEDPxE1?	NF[ySZg{OCCvaX6=	MVHEUXNQ	MULJcohq[mm2aX;uJI9nKEiGQVOyZS=>	M4jJTlI{PDl\|NES5
MDA-MB-231	M1LlRmtqdmG\|ZTDBd5NigQ>?	NWfuSpVxOSEQvF2=	MoTkNlQhcA>?	NGnWPG9FVVOR	NETMXYtKdmirYnn0bY9vKG:oIFjERWM3KGG\|c3Xzd4VlKGG\|IHHj[ZR6dGG2aX;uJIxmfmWuczDv[kB1fWK3bHnu	NXTPb4FVOjN2OUO0OFk>
HS68	NXjlcFdqS3m2b4TvfIlkKEG\|c3H5	NV\XPZpbOTBizszN	MoTpO\|IhcA>?	NHr0WVlFVVOR	M36x[2lEPTB;ND62JO69VQ>?	NWj0TmpxOjN3N{C1OFI>
MEF	M{LwbmN6fG:2b4jpZ{BCe3OjeR?=	MVmxNEDPxE1?	M1frT\|czKGh?	NWfGUnJYTE2VTx?=	NGXFUVdKSzVyPUSuOEDPxE1?	MWqyN\|U4ODV2Mh?=
BGC823	NEPUclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVXFc5FpTE2VTx?=	NEfSTodIUTVyPUOuNFkh\|ryP	M1PwWVI{PjBzN{C2
High5	MVjLbY5ie2ViQYPzZZk>		NXL5[pBoOjRiaB?=		MlTwTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKRFHDOkB4cXSqIFnDOVAhd2ZiMD6wPUDPxE1?	NF;HcI4zOzZyMkWyNy=>
High5	MYXLbY5ie2ViQYPzZZk>		M4rEPFI1KGh?		M{PM[mlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Ehf2m2aDDJR\|UxKG:oIECuNVIh\|ryP	M2TvdVI{PjB{NUKz
High5	NYLCeI5nU2mwYYPlJGF{e2G7		MXeyOEBp		M4\mWWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNVch\|ryP	MXqyN\|YxOjV{Mx?=
A549	NWr5V2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTVcml[TE2VTx?=	MYDJR\|UxRTFwMEe5JO69VQ>?	MX2yN\|Y1PDJzMB?=
HCT116	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MknXSG1UVw>?	MVvJR\|UxRTBwN{W3JO69VQ>?	NHv1UIUzOzZ2NEKxNC=>
K562	NHvmTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3O2RmROW09?	Mlz6TWM2OD1yLk[0OUDPxE1?	NFXjW\|YzOzZ2NEKxNC=>
GBC-SD	NUHDWGIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDKWmc2KM7:TR?=	MoDzO\|IhcA>?	MkHrSG1UVw>?	MXTJR\|UxRTF2Lkig{txO	M3\vRVI{PzB5Mk[w
HGC27	MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXG1JO69VQ>?	MVq3NkBp	M3HEXWROW09?	MWDJR\|UxRTVwNDFOwG0>	Mn7ENlM4ODd{NkC=
HL60	NGn4W4VMcW6jc3WgRZN{[Xl?	M2PESVUh\|ryP	NGr3cnIzPCCq	NH30cYFFVVOR	MlfTTY5pcWKrdHnvckBw\iCKRFHD	MoTYNlM4ODd{NkC=
Vero	M3faRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWm3NkBp	NVrnT4syTE2VTx?=	MYjJR\|UxRTBwOTFOwG0>	NX3Nd\|ZCOjN5OE[0OVI>
NCI60	M37PTmN6fG:2b4jpZ{BCe3OjeR?=		MmDiOFghcA>?	NULBTHZUTE2VTx?=	MU\HTV0xNjV\|IN88US=>	NIfjOXIzPDBzNUOyOy=>
SW620	Mm[5R5l1d3SxeHnjJGF{e2G7		NY\yVGhvPDhiaB?=	NVH3OFZGTE2VTx?=	M3nqU2dKRTBwNUSg{txO	NXjMT49yOjRyMUWzNlc>
U251	MXrDfZRwfG:6aXOgRZN{[Xl?		Mn\TOFghcA>?	NIXkcJJFVVOR	NGLuXmdIUT1zLkWzJO69VQ>?	M1\5U\|I1ODF3M{K3
KM12	MVXDfZRwfG:6aXOgRZN{[Xl?		MlPyOFghcA>?	NXT4c5BJTE2VTx?=	MUnHTV0yNjh6IN88US=>	M{LtdVI1ODF3M{K3
Hs578T	NEfMcHVEgXSxdH;4bYMhSXO\|YYm=		M3LpOVQ5KGh?	NWHsT4hJTE2VTx?=	MX7HTV01Njh\|IN88US=>	M{fSd\|I1ODF3M{K3
MDA-MB-231	NFP6eY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVK2Ums4PDhiaB?=		MWfJR\|UxRTBwMU[g{txO	M1zyclI1ODl3MEG2
MCF7	MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M13zflQ5KGh?		MUTHTV0xNjR3IN88US=>	MlnHNlQyOTl3NUW=
MDA-MB-435	NIrMVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3;GVVQ5KGh?		MVnHTV0xNjh6IN88US=>	NHPwfmszPDFzOUW1OS=>
AsPC1	NYTxNFBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4CyTFMxKM7:TR?=	M2H4dVQ5KGh?	M{H3ZWROW09?	NETCfnRKSzVyPUOuOlYh\|ryP	MVSyOFE5PTN5OB?=
Jurkat E6.1	NEO3eodMcW6jc3WgRZN{[Xl?		NFrwUlMzKGh?	MUTEUXNQ	MnmwTY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1?	NXHtW3JpOjR{NkG4OlI>
KG1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVzLdmlLPDhiaB?=		Mo[3TWM2OD1zLkG1JO69VQ>?	Moi4NlQ2OjVyMEO=
HEL	NVLV[oxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEfVN5A1QCCq	M131SmROW09?	NH[3d5ZKSzVyPUCuOFkh\|ryP	NUnDe4VrOjR4OUSwOVU>
HSC3	NHq1d3NEgXSxdH;4bYMhSXO\|YYm=		NF25UpAyOiCq	NFLNUIVFVVOR	NWXlUY1bUUN3ME2wMlcyKM7:TR?=	NUjFVJZ3OjR5Nk[1OlA>
HT-29	MUfDfZRwfG:6aXOgRZN{[Xl?		MkTMNVIhcA>?	MkS4SG1UVw>?	M{Dwe2lEPTB;MD63NkDPxE1?	NW[w[nROOjR5Nk[1OlA>
KB	MWHDfZRwfG:6aXOgRZN{[Xl?		NXPQcnRDOTJiaB?=	NFzkSFZFVVOR	MY\JR\|UxRTBwN{Wg{txO	NVPGNolwOjR5Nk[1OlA>
H460	NULYN\|NmS3m2b4TvfIlkKEG\|c3H5		NGTRPZYyOiCq	MofKSG1UVw>?	MYHJR\|UxRTBwOEKg{txO	MoDONlQ4PjZ3NkC=
MONE1	NITUbJREgXSxdH;4bYMhSXO\|YYm=		MVqxNkBp	Mm\vSG1UVw>?	NFHpRWtKSzVyPUGuNVgh\|ryP	MXWyOFc3PjV4MB?=
MKN45	MlzrR5l1d3SxeHnjJGF{e2G7		NXriOGU{OTJiaB?=	M3\FR2ROW09?	MmDMTWM2OD1zLkK1JO69VQ>?	NXz5cI5IOjR5Nk[1OlA>
TSGH	Ml;lR5l1d3SxeHnjJGF{e2G7		MWSxNkBp	Mk\ISG1UVw>?	NFXGclNKSzVyPUKuNFkh\|ryP	NE\QSHAzPDd4NkW2NC=>
HL60	M3;IVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVPWW29EPzJiaB?=	M3r6VWROW09?	M{DqfWdKPTB;MD65N{DPxE1?	MVSyOFkxODVyMB?=
HEK293	NHHhdphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M3naR\|czKGh?	NYXDNog4TE2VTx?=	NFryWmJIUTVyPUGzJO69VQ>?	NILlUm8zPDlyMEWwNC=>
Jurkat	MWLDfZRwfG:6aXOgRZN{[Xl?	NEjjUngyODBizszN	Mmj5O\|IhcA>?		NX[5[IV7T0l3ME2wMlkh\|ryP	NGnZdG4zPDlyMEe0Ny=>
GM15850	NITxT41McW6jc3WgRZN{[Xl?	M4LHXlIvPSEQvF2=	MlroPVYhcA>?	MnLLSG1UVw>?	NVq2XI9E\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDNibInzbY5mKDF2IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	NGrXRnIyPjl{MUO2Oy=>
GM15850	NVP4[\|JGU2mwYYPlJGF{e2G7	MUmyMlUh\|ryP	MkTzPVYhcA>?	NWDGWoU6TE2VTx?=	MVTkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgOUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	Mm\ONVY6OjF\|Nke=
GM15850	MV7LbY5ie2ViQYPzZZk>	M{HJbFIvPSEQvF2=	MVy5OkBp	Mnv0SG1UVw>?	NVno[HhM\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF{IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	NV3YVINmOTZ7MkGzOlc>
GM15850	NH\KOIpMcW6jc3WgRZN{[Xl?	MnuwNk42KM7:TR?=	MUG5OkBp	NXrj[\|hVTE2VTx?=	Mojm[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFMhdHm\|aX7lJFkh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	MUCxOlkzOTN4Nx?=
GM15850	MoPhT4lv[XOnIFHzd4F6	M3\UUFIvPSEQvF2=	MVy5OkBp	NH3tZo9FVVOR	NYnPTFFI\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDhiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	MYCxOlkzOTN4Nx?=
GM15850	NGPyTYxMcW6jc3WgRZN{[Xl?	MlW0Nk42KM7:TR?=	M1jtUVk3KGh?	M1jIbGROW09?	NXzlW2pQ\G:nczDuc5QhcW6qaXLpeEBJTEGFIHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGirc4TvcoUhUDRibInzbY5mKDF4IHHj[ZR6dGG2aX;uJI9nKE[[TjDn[Y5m	M{Djc\|E3QTJzM{[3
GM15850	Mo\4SpVv[3Srb36gRZN{[Xl?	NUfsWmRFPSEQvF2=	M2fQelEzKGh?	NEHSZWNFVVOR	MXLoZZMhdm9iZX\m[YN1KG:wIF\YUkBuWk6DIHX4dJJme3Orb36=	MXmxOlkzOTN4Nx?=
U937	MVTLbY5ie2ViQYPzZZk>	MkXrOUDPxE1?	MmrONlQhcA>?	NV;nS2ZjTE2VTx?=	MlS5bIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	MkDpNVc1PDd5NUC=
U937	MXLLbY5ie2ViQYPzZZk>	M2\jWVEh\|ryP	MXuyOEBp	M2DkPGROW09?	M4LuN4hieyCwbzDl[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	MojqNVc1PDd5NUC=
PANC1	MoP2SpVv[3Srb36gRZN{[Xl?	M162eVEh\|ryP	NGfkWXQzPCCq		M4XyO4Rw\XNibn;0JIlv[3KnYYPlJIlvKHB{N3vpdFEh\2WwZTDlfJBz\XO\|aX;u	NYGyeJhrOTd3OEi3OFQ>
PANC1	M3\yTmZ2dmO2aX;uJGF{e2G7	NI\ocY4yKM7:TR?=	NFT6VFQ1QCBiaB?=		MYPkc4V{KG6xdDDpcoNz\WG\|ZTDpckBxOjetaYCxJIdmdmViZYjwdoV{e2mxbh?=	MmHqNVc2QDh5NES=
Caco-2	NWTnRpZVTnWwY4Tpc44hSXO\|YYm=	MkLMOUDPxE1?	MmC2NlQhcA>?	MYnEUXNQ	MWTkc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	Ml64NlAyPDN6NEC=
SCC4	M1TybmZ2dmO2aX;uJGF{e2G7	Mmn0NUDPxE1?	M{HnZ\|ExKG2rbh?=	M4nwS2ROW09?	MULoZZMhdm9iYXfvcol{fCCjY4Tpeol1gSCjdDDWSHIh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGN[WDJ2IHflcoUh\XiycnXzd4lwdg>?	NEm1fJYzODR3MkKyOS=>
A549	MoTMSpVv[3Srb36gRZN{[Xl?	NXvJV2p5PSEQvF2=	M4LlW\|MhcA>?	MmfmSG1UVw>?	M1T5eYRw\XNibn;0JIlv\HWlZTDheZRweGijZ4mgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iTFOzTWk>	MUWyNFg2PTJyOB?=
HCT116	Mnf6T4lv[XOnIFHzd4F6	MkHtNE4{KM7:TR?=	NV7UeWxtOzBiaB?=	NYnTTphyTE2VTx?=	M13qb4Rw\XNibn;0JIlvcGmkaYSgTGRCSzFiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKGirc4TvcoUhUDONOTDhZ4V1gWyjdHnvci=>	NHrNOVEzOTB6ME[0Oy=>
HepG2	NVrVO2FUTnWwY4Tpc44hSXO\|YYm=	M1HVV\|ExKM7:TR?=	NF3nXXczPCCq	M4LIU2ROW09?	NUDEdYFj\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIIC1Ny=>	MVuyNVU1QDV6Mh?=
GM11272	MonGSpVv[3Srb36gRZN{[Xl?	MXOwMlEh\|ryP	MmC5O\|IhcA>?	MXTEUXNQ	NXu4dmR6\G:nczDuc5QhemWjY4TpeoF1\SCPZVPwNkBufXSjboSg[ZhxemW\|c3nvci=>	NEjLWXkzOTh2MEexOi=>
MDA-MB-231	NEW1VnlMcW6jc3WgRZN{[Xl?	MmLHNVAh\|ryP	M1XPWlUhdWmw	NVPxWHR1TE2VTx?=	M1zRcIRw\XNibn;0JIlvcGmkaYSgTGRCSzKj	M3zxRVI{PDl\|NES5
MDA-MB-231	NYfMRpYyU2mwYYPlJGF{e2G7	NUTSfVB4OSEQvF2=	MnTpNlQhcA>?	MY\EUXNQ	M4fB[YRw\XNibn;0JIlvcGmkaYSgTGRCSzZiYYPz[ZN{\WRiYYOgZYNmfHmuYYTpc44hdGW4ZXzzJI9nKHS3YoXsbY4>	MmfwNlM1QTN2NEm=
K562	M33IVGtqdmG\|ZTDBd5NigQ>?				MkPY[I9meyCwb4SgbY5pcWKrdDDISGFE	M2jRZ\|I{PTlzMUGx
Jurkat	NV;aN25wS3m2b4TvfIlkKEG\|c3H5	NUPCV4dOOjBizszN	NGDVWpc4OiCq	MXzEUXNQ	M37S[45wKGO7dH;0c5hq[2m2eTDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvci=>	NW\pZY9{OjR\|MESzOFg>
HCT116	MWrBdI9xfG:\|aYOgRZN{[Xl?	Mn\kN{DPxE1?	M3LOZVI1KGh?	NUP2XnhwTE2VTx?=	M3vrVYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5icEWzJJBzd3SnaX6gcIV3\Wx?	NUewbYhQOjR5Nk[1OlA>
KASUMI-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTl7LkG3JI5O	MWjTRW5ITVJ?
KARPAS-45	Mk\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\UeFJ7UUN3ME2xO\|MvQDlibl2=	MnHnV2FPT0WU
BHT-101	NILuNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn;WTWM2OD1{NESuNVghdk1?	MYPTRW5ITVJ?
H9	NXHCcFY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvkTWM2OD1{NUWuNFQhdk1?	MVHTRW5ITVJ?
PA-1	Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWnJR\|UxRTJ6Nj6yOkBvVQ>?	NGDNTHZUSU6JRWK=
NEC8	NGjnUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjWUYhKSzVyPUK4PU4{QCCwTR?=	M2jmWHNCVkeHUh?=
MHH-PREB-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJ7ND61N{BvVQ>?	MnX5V2FPT0WU
NB7	M4nLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHNTWM2OD1\|NEWuO\|Qhdk1?	NEnKNlRUSU6JRWK=
A3-KAW	NIjBe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTRyMD61PUBvVQ>?	MXjTRW5ITVJ?
NB69	NYTufGJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTRzMT63NUBvVQ>?	NVzQOm9WW0GQR1XS
EoL-1-cell	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTR3NEK1JI5O	MYXTRW5ITVJ?
CHP-212	NGGxbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[zTWM2OD12NUeuOVMhdk1?	NUPOfGx[W0GQR1XS
C2BBe1	NEjTOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|UxRTR5Mj6xPUBvVQ>?	NWfTXFdMW0GQR1XS
697	NIH1TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\NSGlEPTB;NEezMlQyKG6P	M{ntRnNCVkeHUh?=
BCPAP	NFTPSHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTVyMT60NkBvVQ>?	MYfTRW5ITVJ?
L-363	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7oNphKSzVyPUWwN{4yKG6P	MVLTRW5ITVJ?
ES8	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;4dnpKSzVyPUWyN{42OyCwTR?=	MYTTRW5ITVJ?
BE-13	M{W5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTV{Nj65OkBvVQ>?	M3H1cnNCVkeHUh?=
CTB-1	NIDTVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLkTWM2OD13M{euPVIhdk1?	MmnHV2FPT0WU
HD-MY-Z	M{fEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDsUJJsUUN3ME21N\|gvOTNibl2=	M2nZSnNCVkeHUh?=
NKM-1	NVTZO4NuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3UdFdKSzVyPUW0OE4zPyCwTR?=	NEfDbJZUSU6JRWK=
NCI-H720	MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUnJR\|UxRTV4MD6xPEBvVQ>?	M2\KNHNCVkeHUh?=
KY821	M{LuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnjeodtUUN3ME21OlMvOjVibl2=	MVnTRW5ITVJ?
OVCAR-5	M2PrVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlv2TWM2OD13N{[uNVEhdk1?	M17J[XNCVkeHUh?=
CTV-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnPWmtbUUN3ME21PFEvPTZibl2=	M2C4cXNCVkeHUh?=
P12-ICHIKAWA	NHzzWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTV7Nj61NUBvVQ>?	NHXhWpVUSU6JRWK=
DB	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2P4b2lEPTB;NUm4MlU4KG6P	NV\qWGlqW0GQR1XS
CHL-1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XIXWlEPTB;NkSyMlA5KG6P	MlTRV2FPT0WU
A4-Fuk	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjxS4x7UUN3ME22OFQvQTFibl2=	NG\oV\|BUSU6JRWK=
MV-4-11	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvWO5dKSzVyPU[1PU4yKG6P	MVTTRW5ITVJ?
RPMI-8226	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEPW[3hKSzVyPU[3PE4yQCCwTR?=	NX;3O4lEW0GQR1XS
NB14	NXT6WGd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTZ7Nj65OUBvVQ>?	NYThPJhyW0GQR1XS
DOHH-2	NVLOXmU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULnNml7UUN3ME23NFYvPjhibl2=	M4m2fnNCVkeHUh?=
D-423MG	NWTTdZI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnnRpREUUN3ME23NFYvQDlibl2=	M3jSNXNCVkeHUh?=
D-283MED	NIfPWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlO2TWM2OD15MUSuNVQhdk1?	M{[wXXNCVkeHUh?=
ES1	NGLyS41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnDTWM2OD15MkSuOEBvVQ>?	M3fWR3NCVkeHUh?=
GOTO	Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\FU5FKSzVyPUeyPU4yOiCwTR?=	MlXRV2FPT0WU
NCI-H209	NH\XOnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXGXmxKSzVyPUeyPU46KG6P	MVnTRW5ITVJ?
MOLT-13	NGrGXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDsTWM2OD15M{iuPVghdk1?	MVjTRW5ITVJ?
ATN-1	M3zHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHjTWM2OD15NECuNlghdk1?	MUTTRW5ITVJ?
DU-4475	M3PZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTd3MT65NUBvVQ>?	Mm\IV2FPT0WU
NB10	NUP3Vo9OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XSSGlEPTB;N{WxMlkzKG6P	MmTlV2FPT0WU
KG-1	M4flVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;kfYJTUUN3ME23O\|UvPDVibl2=	M4HzR3NCVkeHUh?=
MOLT-4	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7ucYRKSzVyPUe4O{41PiCwTR?=	NGLnS\|NUSU6JRWK=
TE-1	NVTlRllUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvsZmFPUUN3ME23PVEvOSCwTR?=	MXPTRW5ITVJ?
SBC-1	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[yTodKSzVyPUe5N{45PCCwTR?=	Ml24V2FPT0WU
HEL	Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnifndwUUN3ME24NFYvODhibl2=	MXvTRW5ITVJ?
SK-MEL-2	NH3T[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{mwTmlEPTB;OEC5MlQ1KG6P	NGTTe4tUSU6JRWK=
KU812	M1LpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTZTWM2OD16MUOuNUBvVQ>?	NXPIbGtqW0GQR1XS
RPMI-8866	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vBZWlEPTB;OEGzMlY4KG6P	NVXYWpB4W0GQR1XS
ALL-PO	M{T1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4foWGlEPTB;OEG0MlY3KG6P	M4D2bXNCVkeHUh?=
LU-139	NWC3NJBGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlf0TWM2OD16MkKuPFYhdk1?	NVTSV4toW0GQR1XS
RS4-11	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\PTWM2OD16M{KuOFUhdk1?	MU\TRW5ITVJ?
EW-18	NXH6RXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3PvR2lEPTB;OEOyMlk3KG6P	M{LyVnNCVkeHUh?=
P30-OHK	NY\aSXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnkTmlFUUN3ME24N\|UvPyCwTR?=	MVPTRW5ITVJ?
D-566MG	NHvBU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XRWWlEPTB;OEO4MlYzKG6P	NWfJcGFkW0GQR1XS
HSC-4	NH3oXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPsTWM2OD16NE[uOVEhdk1?	M4fsXnNCVkeHUh?=
QIMR-WIL	M{ixcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTh4Mj6wN{BvVQ>?	NIXSWJhUSU6JRWK=
SW954	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULFWIFYUUN3ME24OlMvOTZibl2=	MUXTRW5ITVJ?
HGC-27	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTh5Mj6zOEBvVQ>?	MY\TRW5ITVJ?
HH	NFPmcmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTh7ND6xNkBvVQ>?	NG\XN2tUSU6JRWK=
KE-37	M3;hV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zWNGlEPTB;OEm0MlYzKG6P	NVPtd4NHW0GQR1XS
SK-N-DZ	NVfEc4JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\1SopKSzVyPUmwNE41OyCwTR?=	MUfTRW5ITVJ?
J-RT3-T3-5	NVrBWVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYruVmdVUUN3ME25NVAvPDlibl2=	Mn;HV2FPT0WU
A427	NUHuVWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvmTWM2OD17MkCuPFQhdk1?	NXvVUnB6W0GQR1XS
ECC10	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\UeIpEUUN3ME25OFUvQDdibl2=	MonXV2FPT0WU
EW-1	NXf2cVhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3kdoJKSzVyPUm0O{4zPiCwTR?=	M4O1R3NCVkeHUh?=
MIA-PaCa-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1O3N2lEPTB;OUS5MlEzKG6P	NETIdmdUSU6JRWK=
HCC2218	NFHqToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;TVHZIUUN3ME25OVgvPDhibl2=	MkL4V2FPT0WU
HAL-01	M1LjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7QdXljUUN3ME25OlgvODRibl2=	MnH5V2FPT0WU
RD	NWnDbIN6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;YTWM2OD17N{SuOFUhdk1?	NYDYSYt3W0GQR1XS
SK-N-AS	NYrKOolST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTl6OD6xJI5O	MoqyV2FPT0WU
ML-2	NUPaNldVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\sPIwzUUN3ME2xMlAxPDB5IN88US=>	MUnTRW5ITVJ?
MEL-HO	NELROZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTFwMEC1PFIh\|ryP	NVvTcGlOW0GQR1XS
MS-1	NUXHT3RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX6xelhJUUN3ME2xMlAxPjF5IN88US=>	MXzTRW5ITVJ?
NCI-SNU-1	NICyWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknNTWM2OD1zLkCyN\|MyKM7:TR?=	MnHEV2FPT0WU
8505C	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVr0ZpZHUUN3ME2xMlAzOzNzIN88US=>	MkPFV2FPT0WU
MN-60	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1G4bGlEPTB;MT6wNlY5KM7:TR?=	MnW0V2FPT0WU
SAS	M1jNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVP4fnR4UUN3ME2xMlA1ODhzIN88US=>	M4XoUnNCVkeHUh?=
EFM-19	NYPyWZR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHCSHlKSzVyPUGuNFQ5PzlizszN	M1LPeXNCVkeHUh?=
Ca9-22	M2LmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\nRWlEPTB;MT6wOVExPyEQvF2=	MUXTRW5ITVJ?
NBsusSR	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXjcVdKSzVyPUGuNFUyPjZizszN	MWnTRW5ITVJ?
NB13	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T4NGlEPTB;MT6wOVUxOSEQvF2=	NWLU[5JqW0GQR1XS
SF295	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHwOm5JUUN3ME2xMlA3PjJ2IN88US=>	MoXhV2FPT0WU
U-2-OS	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVSxSmJ6UUN3ME2xMlA4QTFzIN88US=>	NUTnUG12W0GQR1XS
NCI-H526	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTFwMEiyPVEh\|ryP	MmTFV2FPT0WU
KMOE-2	NWXUXGY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTFwMEm0NlIh\|ryP	M2Kzb3NCVkeHUh?=
RCM-1	NHuyRmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MleyTWM2OD1zLkGyNVAzKM7:TR?=	M3vuVXNCVkeHUh?=
MC116	NIXaWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rERWlEPTB;MT6xN\|YzOSEQvF2=	MXLTRW5ITVJ?
NCI-H1092	NEDHTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTFwMUW0NFYh\|ryP	NXrIXpp5W0GQR1XS
EW-3	NGPKWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXaUXBKSzVyPUGuNVczOTJizszN	MVXTRW5ITVJ?
HCT-116	NH;Ud4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDFS3R4UUN3ME2xMlE4PzVizszN	MUfTRW5ITVJ?
MC-IXC	NWq0[I9pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnOSXEzUUN3ME2xMlE4QDhzIN88US=>	M3XafHNCVkeHUh?=
LB1047-RCC	NWfIeWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nIUWlEPTB;MT6xPFMyOiEQvF2=	M1zyUnNCVkeHUh?=
VM-CUB-1	M{\E[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoP4TWM2OD1zLkG5NVA5KM7:TR?=	MkXWV2FPT0WU
NB5	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmfDTWM2OD1zLkG5PFU3KM7:TR?=	NInwVpdUSU6JRWK=
SKG-IIIa	NVv5OWU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPRfmZKSzVyPUGuNlM1PjRizszN	M4\wUHNCVkeHUh?=
HO-1-N-1	M3vxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIroTVBKSzVyPUGuNlM5OzVizszN	M4rmdnNCVkeHUh?=
EFO-27	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVu3N4hoUUN3ME2xMlI2ODR\|IN88US=>	Ml7XV2FPT0WU
MHH-NB-11	NFHHS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfRTWM2OD1zLkK4N\|I6KM7:TR?=	M4PN[XNCVkeHUh?=
SW620	M2Xacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTFwMkmwNVgh\|ryP	NYTiUpR4W0GQR1XS
MOLT-16	MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXP0dJF5UUN3ME2xMlI6Pzl5IN88US=>	MV7TRW5ITVJ?
NTERA-S-cl-D1	NHnlT4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrlTWM2OD1zLkOxO\|YyKM7:TR?=	NXPVZ45ZW0GQR1XS
VA-ES-BJ	NFH1T3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{P5bGlEPTB;MT6zNlQ4PyEQvF2=	NYPHbmw1W0GQR1XS
HCC1419	NH\ONXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTFwM{SwNlch\|ryP	MmjYV2FPT0WU
NCI-H69	NEL0PGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXNXI5DUUN3ME2xMlM1OTF{IN88US=>	NWHh[4xrW0GQR1XS
DEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWLJR\|UxRTFwM{WxOlIh\|ryP	M33xOnNCVkeHUh?=
LXF-289	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTFwM{WyOEDPxE1?	Mo\aV2FPT0WU
EW-11	NX;mfpNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK4e2FUUUN3ME2xMlM3ODJ4IN88US=>	M{THenNCVkeHUh?=
KP-4	MnHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrrb\|dKSzVyPUGuN\|cxQDVizszN	NHntVWlUSU6JRWK=
NOS-1	MknoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTM[opKSzVyPUGuOFEyQTRizszN	MnPFV2FPT0WU
SK-NEP-1	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFwNEG2PVMh\|ryP	MnHGV2FPT0WU
LAMA-84	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXRSYpKSzVyPUGuOFM6PDVizszN	M1\2dXNCVkeHUh?=
ES5	NU\IcZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPNTWM2OD1zLkS0N{DPxE1?	NXzDe2dJW0GQR1XS
HuO9	NHHnV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\vPGdKSzVyPUGuOFU{PjJizszN	MnnrV2FPT0WU
COLO-684	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTFwNE[xNVgh\|ryP	Mnj6V2FPT0WU
EW-24	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\hNoUzUUN3ME2xMlQ3PTNzIN88US=>	MnTEV2FPT0WU
BV-173	M{PkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXHTWM2OD1zLkS3NlkyKM7:TR?=	MmP0V2FPT0WU
NCI-H1770	M3;GOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFwNEi1N\|Yh\|ryP	Ml3FV2FPT0WU
HuP-T4	NXHR[pZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEPhVmhKSzVyPUGuOFk{KM7:TR?=	MXPTRW5ITVJ?
TYK-nu	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnrOFNKSzVyPUGuOFk5PTFizszN	Mki5V2FPT0WU
YH-13	NVK1b5dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPoTWM2OD1zLkS5PFk1KM7:TR?=	NGTm[ZdUSU6JRWK=
H4	NUS2R3NrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXVflBKSzVyPUGuOVA6OTJizszN	NULmZ2pHW0GQR1XS
OVCAR-8	M4LjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2TV[GlEPTB;MT61OFQ4PyEQvF2=	MmTDV2FPT0WU
NCI-H23	MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXjJR\|UxRTFwNUS2OFUh\|ryP	NHf5c4RUSU6JRWK=
ES7	NEHHWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTTPZVKSzVyPUGuOVQ4PzNizszN	NXnW[JlQW0GQR1XS
COR-L88	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTFwNU[0NlQh\|ryP	NHjxemhUSU6JRWK=
TI-73	M3rr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXrV2ZHUUN3ME2xMlU6ODZizszN	MkfWV2FPT0WU
RT-112	NWXaelVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTFwNUmyPFQh\|ryP	NGXaU5pUSU6JRWK=
HuO-3N1	M3f0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3tNopKSzVyPUGuOVk{QDVizszN	MUnTRW5ITVJ?
HC-1	M2LHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\2TWM2OD1zLkW5PFY3KM7:TR?=	MlL6V2FPT0WU
HT55	M{LMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;aS2lEPTB;MT62OVE{OSEQvF2=	NHfQV5FUSU6JRWK=
IA-LM	M{H1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\OfnpzUUN3ME2xMlY6Ojd6IN88US=>	NF[1OoJUSU6JRWK=
EM-2	NVq0Z5FET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTFwN{CwNVQh\|ryP	MV7TRW5ITVJ?
MHH-ES-1	M{n6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITRSIdKSzVyPUGuO\|A1OzVizszN	NETDbHZUSU6JRWK=
CAL-27	NWfCdpYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX7XTlN5UUN3ME2xMlcxPjJzIN88US=>	NU\KWZdOW0GQR1XS
COLO-800	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXZUHhVUUN3ME2xMlcyOTd7IN88US=>	NXzTOIZzW0GQR1XS
HCE-T	M1G1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHqTWM2OD1zLkexOUDPxE1?	M4HZO3NCVkeHUh?=
CAMA-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfGTWM2OD1zLkexPVcyKM7:TR?=	M4W3eHNCVkeHUh?=
LOXIMVI	M{fUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTFwN{KxNUDPxE1?	NUXpNJA2W0GQR1XS
NH-12	MoPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3i5Z2lEPTB;MT63NlY6OSEQvF2=	M4jKeXNCVkeHUh?=
TCCSUP	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DRc2lEPTB;MT63NlgzQSEQvF2=	M3[wdXNCVkeHUh?=
MDA-MB-361	NH2xR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFwN{OxOVch\|ryP	NW\RXHFDW0GQR1XS
EW-16	M1zyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPaR5hKSzVyPUGuO\|QyODdizszN	MXzTRW5ITVJ?
SNU-423	NFnoZYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TYZ2lEPTB;MT63OVgzPyEQvF2=	NX3rWHJUW0GQR1XS
Daoy	NWjse\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M135VWlEPTB;MT63OlMyQSEQvF2=	M{fnNnNCVkeHUh?=
ES4	M3nYUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDkW4V[UUN3ME2xMlc5PzRzIN88US=>	M2TwWHNCVkeHUh?=
PFSK-1	M1HPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;5eWlEPTB;MT64NFM4KM7:TR?=	NF7COIlUSU6JRWK=
ES3	NWr4WJBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4f1ZmlEPTB;MT64NlY5OSEQvF2=	M3qyN3NCVkeHUh?=
ONS-76	NEnBcnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXXRYRKSzVyPUGuPFI5QTdizszN	NYj2WpBTW0GQR1XS
JVM-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTFwOEW0OVEh\|ryP	MkLvV2FPT0WU
OS-RC-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULMUnNZUUN3ME2xMlg4OTVzIN88US=>	MWjTRW5ITVJ?
COLO-320-HSR	NX7GbGVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXPW4JTUUN3ME2xMlg5OTl5IN88US=>	MY\TRW5ITVJ?
HN	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYW0R3Y2UUN3ME2xMlg5PzJ3IN88US=>	M3faNnNCVkeHUh?=
HT	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXLVmxKSzVyPUGuPFg6PDdizszN	NWD1c4JDW0GQR1XS
LoVo	NYnIdlByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlj4TWM2OD1zLki5PFEh\|ryP	NXjCSZh1W0GQR1XS
CGTH-W-1	M3TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXS[YZKSzVyPUGuPFk6PDZizszN	MmjCV2FPT0WU
NB6	NFvscWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljGTWM2OD1zLkmxNlk5KM7:TR?=	MmLIV2FPT0WU
EW-22	M2PwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LJZ2lEPTB;MT65Nlg5PyEQvF2=	NXnBeoRuW0GQR1XS
ES6	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2r4R2lEPTB;MT65N\|Y{OSEQvF2=	M1nvVnNCVkeHUh?=
SCC-15	NXm5NpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTHTWM2OD1zLkmzPFE6KM7:TR?=	NE\tco9USU6JRWK=
HL-60	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTFwOUO5NFIh\|ryP	M1zoZ3NCVkeHUh?=
human HOP-92	NX7EdGtWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLGTWM2OD1zLkm0NFY2KM7:TR?=	MUjTRW5ITVJ?
SW626	M{H2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHi5THpKSzVyPUGuPVQ5QTlizszN	MnrxV2FPT0WU
HEC-1	M2T2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkD5TWM2OD1zLkm1N\|Yh\|ryP	NVPjcJlGW0GQR1XS
LB2241-RCC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTDTWM2OD1zLkm4NlMyKM7:TR?=	NUjINYNOW0GQR1XS
Ramos-2G6-4C10	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHT4e\|JKSzVyPUGuPVk1QTNizszN	NHH5NW5USU6JRWK=
A101D	NYHzV2JzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJwMkCzNFMh\|ryP	MmToV2FPT0WU
NCI-H446	MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrZbWhKSzVyPUKuNFQ2QTlizszN	MYrTRW5ITVJ?
SBC-5	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;OOZZyUUN3ME2yMlA3OTR5IN88US=>	MlXtV2FPT0WU
HOS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDRN\|VlUUN3ME2yMlA4PjV\|IN88US=>	MXHTRW5ITVJ?
K5	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlr5TWM2OD1{LkC3PFEyKM7:TR?=	Mn;rV2FPT0WU
HLE	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIr3Rm5KSzVyPUKuNFg2OjlizszN	MYXTRW5ITVJ?
HSC-2	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3wTWM2OD1{LkGyPFk5KM7:TR?=	NXfOR25mW0GQR1XS
LCLC-97TM1	M2DTUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknsTWM2OD1{LkG0OVg{KM7:TR?=	MXHTRW5ITVJ?
DMS-273	NEnaOJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjVb5FzUUN3ME2yMlE1QDN5IN88US=>	M2LE[XNCVkeHUh?=
TE-8	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVO1eWVnUUN3ME2yMlE2PzZ3IN88US=>	MkXiV2FPT0WU
DSH1	NWKzcYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT1[JJKSzVyPUKuNVY{QThizszN	MVHTRW5ITVJ?
CAL-51	M1\JPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLJTWM2OD1{LkG2Olk6KM7:TR?=	M13ud3NCVkeHUh?=
IST-SL1	NHXJR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVWx[4d2UUN3ME2yMlE3QDR2IN88US=>	MXXTRW5ITVJ?
GCT	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXUdJNKSzVyPUKuNVc4PyEQvF2=	M17wW3NCVkeHUh?=
SW948	M{Tn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTJwMUi0OVYh\|ryP	M3XlWXNCVkeHUh?=
NOMO-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTJwMUmzNVch\|ryP	NVfZVm41W0GQR1XS
C8166	M2K5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWKySWh1UUN3ME2yMlIyOzN2IN88US=>	M2P2[XNCVkeHUh?=
OC-314	NF2z[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjkWZloUUN3ME2yMlI{OjV7IN88US=>	NUP5S4xGW0GQR1XS
CAL-39	M4rxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDu[WFKSzVyPUKuNlM3OjZizszN	NV;2[3J{W0GQR1XS
MDA-MB-453	NX3G[IJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELKNoZKSzVyPUKuNlQzPzVizszN	MULTRW5ITVJ?
A673	NIDkZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\VTWM2OD1{LkK1PFYzKM7:TR?=	M1vJd3NCVkeHUh?=
HTC-C3	M332eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJwMk[4OUDPxE1?	NYPCXoc6W0GQR1XS
NCI-H1666	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rsbGlEPTB;Mj6yPFEyOSEQvF2=	MVjTRW5ITVJ?
PSN1	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;aSXhKSzVyPUKuNlg6OTNizszN	MVLTRW5ITVJ?
GI-1	NX7PVHc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoSwTWM2OD1{LkOwOVQ{KM7:TR?=	NVixSJh[W0GQR1XS
HuH-7	M2\5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTJwM{C2N\|ch\|ryP	NYGwVYFCW0GQR1XS
JAR	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmW5TWM2OD1{LkOxPVg4KM7:TR?=	NEPSPZBUSU6JRWK=
5637	M4TVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXmW\|lmUUN3ME2yMlMzOTJ7IN88US=>	NGrKcHBUSU6JRWK=
GB-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;JWGlEPTB;Mj6zNlM{PSEQvF2=	MY\TRW5ITVJ?
KP-N-YS	NFuy[nhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXsPW5KSzVyPUKuN\|I3OTVizszN	MWPTRW5ITVJ?
OAW-42	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3q0TGlEPTB;Mj6zN\|QyPiEQvF2=	NWr0NXY1W0GQR1XS
8-MG-BA	NV3QSm1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJwM{O5NFYh\|ryP	NX33S3ZGW0GQR1XS
RH-18	NEe0XYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPDUZlKSzVyPUKuN\|UxOjJizszN	NF[5W2xUSU6JRWK=
NCI-H1155	NYHOW\|liT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1zES2lEPTB;Mj6zOlczPSEQvF2=	NI\MVFhUSU6JRWK=
NB17	NI\oTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3aOnZRUUN3ME2yMlM5OjR\|IN88US=>	NXixdoVuW0GQR1XS
NCI-H1437	MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoO5TWM2OD1{LkSxPFc{KM7:TR?=	NIXrXVFUSU6JRWK=
SN12C	NYfpN2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;LR45KSzVyPUKuOFMzOTRizszN	M4HBeHNCVkeHUh?=
HSC-3	NHPZ[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXZR2ZKSzVyPUKuOFQ2ODlizszN	MUfTRW5ITVJ?
GAMG	NWXBZ49nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3T4c2lEPTB;Mj60OFU3OSEQvF2=	MVzTRW5ITVJ?
HT-1080	M4TjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XHW2lEPTB;Mj60OFg3PCEQvF2=	M3HlSXNCVkeHUh?=
A549	M33SZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJwNES4PVMh\|ryP	NHTZcnlUSU6JRWK=
KNS-62	NIqxV2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DHRmlEPTB;Mj60OVA3OSEQvF2=	M4DKbnNCVkeHUh?=
YKG-1	M4jYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nofWlEPTB;Mj60OVQ{PyEQvF2=	M2m4XHNCVkeHUh?=
LU-134-A	NIXMd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHKdpJKSzVyPUKuOFcxODhizszN	M1jsWXNCVkeHUh?=
FADU	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUftNYNZUUN3ME2yMlQ4OTZ{IN88US=>	NYPaV25xW0GQR1XS
TGBC11TKB	M1LwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\oTWM2OD1{LkS3NVc4KM7:TR?=	NUnwSWlHW0GQR1XS
HT-3	MlnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL3Xmg4UUN3ME2yMlQ6PTN3IN88US=>	M3PidHNCVkeHUh?=
NCI-H2170	M1X3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTLTGJmUUN3ME2yMlUxPTR7IN88US=>	NHnYdphUSU6JRWK=
Mo-T	NFLLcWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLKTWM2OD1{LkWwPVI4KM7:TR?=	NVv1U\|dyW0GQR1XS
CCRF-CEM	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInUXVVKSzVyPUKuOVMxPDNizszN	MojsV2FPT0WU
KU-19-19	NVS0[4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTJwNUO1NVMh\|ryP	Mm\DV2FPT0WU
NCI-H1048	NEDmXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mkj4TWM2OD1{LkW1NFI2KM7:TR?=	NGnqc2VUSU6JRWK=
KOSC-2	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrHO2RkUUN3ME2yMlU3ODd4IN88US=>	NVK3b2xMW0GQR1XS
A431	M{[0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jmVGlEPTB;Mj61OlM{PSEQvF2=	MmPmV2FPT0WU
COR-L23	M{jXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmO4TWM2OD1{LkW4OVY3KM7:TR?=	M1j5bXNCVkeHUh?=
MKN28	M4nx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJwNUmwN\|ch\|ryP	NGDyfJRUSU6JRWK=
22RV1	M{L5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWe4U5BoUUN3ME2yMlU6Ojd2IN88US=>	Mo\DV2FPT0WU
ABC-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWe2[YJqUUN3ME2yMlYxPDZizszN	NWTCNItUW0GQR1XS
NCI-H2126	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlK5TWM2OD1{Lk[wPVg1KM7:TR?=	MUjTRW5ITVJ?
DoTc2-4510	NUTIPZpQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTnU3NKSzVyPUKuOlIyQDVizszN	MWjTRW5ITVJ?
SCC-4	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPPWphJUUN3ME2yMlY{ODF{IN88US=>	NXnXOVNzW0GQR1XS
NCI-H661	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTQfHR6UUN3ME2yMlY1ODh3IN88US=>	MkD3V2FPT0WU
RPMI-2650	NU[wTZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHNWo9tUUN3ME2yMlY1OTR\|IN88US=>	NELVW4NUSU6JRWK=
NCI-H510A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWr0RnNpUUN3ME2yMlY1PDJ4IN88US=>	M3HMPXNCVkeHUh?=
BPH-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjFU3FKSzVyPUKuOlU5PSEQvF2=	MUjTRW5ITVJ?
M14	NXv6RpBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\rTWM2OD1{Lk[2PVk{KM7:TR?=	MU\TRW5ITVJ?
G-402	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfKOmpJUUN3ME2yMlcxPDVzIN88US=>	NFHrNVZUSU6JRWK=
AsPC-1	NFHmRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\oXZBKSzVyPUKuO\|EyPyEQvF2=	MUHTRW5ITVJ?
NB12	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zPVWlEPTB;Mj63NVcyKM7:TR?=	MV7TRW5ITVJ?
SK-HEP-1	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHm0ZXBKSzVyPUKuO\|Q{QTFizszN	MkPVV2FPT0WU
U-266	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fGbWlEPTB;Mj63O\|EzOSEQvF2=	NV\iO3FYW0GQR1XS
AM-38	M1fDdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvKSXlKSzVyPUKuO\|c{PTVizszN	MlKyV2FPT0WU
PC-14	NGPUdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LxXWlEPTB;Mj64NFUyKM7:TR?=	NH[2WG1USU6JRWK=
EGI-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXn5enFMUUN3ME2yMlgyPzR\|IN88US=>	MUnTRW5ITVJ?
LS-411N	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrxTWM2OD1{LkiyN\|Mh\|ryP	Mn;mV2FPT0WU
BFTC-905	M3TsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHXUZJ5UUN3ME2yMlg2PTJ\|IN88US=>	M3XheXNCVkeHUh?=
CaR-1	NUmweVg2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHJTWM2OD1{Lki2JO69VQ>?	MmTPV2FPT0WU
NCI-H292	M4nJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEf3UY5KSzVyPUKuPFY2QTZizszN	MV7TRW5ITVJ?
8305C	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTJwOE[2OFUh\|ryP	NUPofZk1W0GQR1XS
SNU-449	NH;BRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXiSYRKSzVyPUKuPFkyQDJizszN	Mn[0V2FPT0WU
LCLC-103H	M4nkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUCxUopIUUN3ME2yMlkxPDN6IN88US=>	NW\mU4s4W0GQR1XS
SW1573	MlP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTJwOU[wPFIh\|ryP	Mn3XV2FPT0WU
MLMA	M4ThcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnGxTWM2OD1{Lkm2O\|E4KM7:TR?=	NH7seHhUSU6JRWK=
NCI-H1355	MmKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17ZeGlEPTB;Mz6wNFc6PiEQvF2=	MYPTRW5ITVJ?
RMG-I	NIXNNJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXXd2JKSzVyPUOuNFI2QTJizszN	NXz2ZWx5W0GQR1XS
BB65-RCC	NIXrTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjITFZvUUN3ME2zMlA{OzF2IN88US=>	NI\lbXNUSU6JRWK=
PC-3	NVLtSFNtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fwS2lEPTB;Mz6wN\|g4PCEQvF2=	M{jhcHNCVkeHUh?=
SF268	NGHSbHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TlXmlEPTB;Mz6wOFUzOyEQvF2=	MY\TRW5ITVJ?
NCI-H810	Ml;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LTcGlEPTB;Mz6wOFgzOyEQvF2=	NVLlOo1wW0GQR1XS
MEG-01	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TCVmlEPTB;Mz6wOlE3PCEQvF2=	MmTpV2FPT0WU
SW13	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjMTJByUUN3ME2zMlA4QDR5IN88US=>	M3nuUHNCVkeHUh?=
RH-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFzrTZNKSzVyPUOuNVAzPzhizszN	M1PWRnNCVkeHUh?=
GT3TKB	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTiXnExUUN3ME2zMlEyOjh\|IN88US=>	M{\YNHNCVkeHUh?=
TK10	NGPjWVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rPb2lEPTB;Mz6xN\|czPCEQvF2=	MULTRW5ITVJ?
T-24	NFvzOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnCVohKSzVyPUOuNVUxPyEQvF2=	M37SXHNCVkeHUh?=
A498	Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT1ZlI{UUN3ME2zMlIxQDdzIN88US=>	NYLzNm5jW0GQR1XS
GR-ST	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoP2TWM2OD1\|LkKyNVM6KM7:TR?=	Mle3V2FPT0WU
LB2518-MEL	NUH1fFVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnpXHBDUUN3ME2zMlIzOzl6IN88US=>	NVH1[WFUW0GQR1XS
T47D	M2LYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV;l[25MUUN3ME2zMlI{PjJ5IN88US=>	NGjPSGVUSU6JRWK=
NCI-H1651	MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoK5TWM2OD1\|LkK0OlQ1KM7:TR?=	NV7BO3RpW0GQR1XS
EC-GI-10	NWCySWVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\NOGlEPTB;Mz6yOlE2OyEQvF2=	MX3TRW5ITVJ?
HT-29	M3q5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvpSHNmUUN3ME2zMlI3PjF2IN88US=>	NHHVOG1USU6JRWK=
GI-ME-N	NXrUfXpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGryWYdKSzVyPUOuNlk2OTFizszN	MULTRW5ITVJ?
SW756	NFKxSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7zZYlKSzVyPUOuNlk3OjlizszN	MUHTRW5ITVJ?
RKO	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvIW\|hLUUN3ME2zMlMxPzV5IN88US=>	M4H4O3NCVkeHUh?=
NCI-H1563	MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLMe2hKSzVyPUOuN\|MxOThizszN	MnfZV2FPT0WU
DJM-1	NEH0WHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfXbYtIUUN3ME2zMlM4Pjd2IN88US=>	MWDTRW5ITVJ?
L-428	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTNwNECwOFUh\|ryP	NWLidoNoW0GQR1XS
NCI-H2122	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTNwNEGzNVIh\|ryP	NGnRdoJUSU6JRWK=
Ca-Ski	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{CydWlEPTB;Mz60OVQ{KM7:TR?=	M{LjSHNCVkeHUh?=
639-V	NYHyPIpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlHmTWM2OD1\|LkS2NFU4KM7:TR?=	NEjPVYhUSU6JRWK=
SW1116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPJTWM2OD1\|LkS2NlY6KM7:TR?=	NIHT[nlUSU6JRWK=
DMS-114	MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrMTWM2OD1\|LkS3NFY3KM7:TR?=	Ml[2V2FPT0WU
MZ2-MEL	NEHiUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfiO2RWUUN3ME2zMlQ4PjhzIN88US=>	MYfTRW5ITVJ?
COLO-829	NXvZdmU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HWVGlEPTB;Mz61NFA4OyEQvF2=	M1nIW3NCVkeHUh?=
J82	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nITGlEPTB;Mz61NFU4KM7:TR?=	NYf6TnlEW0GQR1XS
EW-13	M1HMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTNwNUK1NUDPxE1?	NXm2SZhyW0GQR1XS
RXF393	NImwfHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\kOJlKSzVyPUOuOVMzQTRizszN	NIrSR2NUSU6JRWK=
CAL-62	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTNwNUS1NVQh\|ryP	NGfjfo9USU6JRWK=
OCUB-M	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTNwNUS2OlUh\|ryP	M3fqNHNCVkeHUh?=
BT-474	NHLQSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DsUWlEPTB;Mz62N\|MyKM7:TR?=	MWHTRW5ITVJ?
KYSE-180	NGfBXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\XXGlEPTB;Mz62N\|M4OiEQvF2=	M4W4eXNCVkeHUh?=
NCI-H650	M3XvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[0TWM2OD1\|Lk[0Nlg4KM7:TR?=	MnvlV2FPT0WU
Detroit562	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV[3c3RXUUN3ME2zMlY2ODJ{IN88US=>	NFfIZo9USU6JRWK=
SW48	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILZbm5KSzVyPUOuOlU3PTdizszN	M2rjVnNCVkeHUh?=
KYSE-450	NGnM[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrqTWM2OD1\|Lk[4OVgzKM7:TR?=	NVTlXXdmW0GQR1XS
KYSE-510	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTNwN{KxPFEh\|ryP	NH;XSmJUSU6JRWK=
GP5d	M{PiZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTNwN{K5OUDPxE1?	MkjEV2FPT0WU
RPMI-7951	MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmK3TWM2OD1\|Lke0O\|I{KM7:TR?=	M1;IOHNCVkeHUh?=
Becker	M{\ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1j2[mlEPTB;Mz63OVAyOiEQvF2=	MorrV2FPT0WU
WM-115	NGD3XpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjyRpFVUUN3ME2zMlc5OTl3IN88US=>	MoX0V2FPT0WU
G-401	NF;KZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfjTWM2OD1\|Lke5NFg2KM7:TR?=	NGjpUoZUSU6JRWK=
PANC-08-13	M2TlXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPJTWM2OD1\|Lke5OlAzKM7:TR?=	NVvkU4dZW0GQR1XS
SW982	NGfFd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTNwOEC1OVEh\|ryP	MULTRW5ITVJ?
D-263MG	Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEH4PFVKSzVyPUOuPFIxPTFizszN	M1zvN3NCVkeHUh?=
KM-H2	M{T6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkn3TWM2OD1\|LkiyOlI1KM7:TR?=	M1n0d3NCVkeHUh?=
SK-MEL-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITNW5dKSzVyPUOuPFI5PDFizszN	MnXpV2FPT0WU
NCI-H1581	NH:2cXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\UNGlEPTB;Mz64OFQ5QCEQvF2=	MUTTRW5ITVJ?
LS-123	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTNwOEe5NFkh\|ryP	NFjKWY9USU6JRWK=
CAKI-1	MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4j0SmlEPTB;Mz64PVA2OiEQvF2=	M1fsdXNCVkeHUh?=
MEL-JUSO	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3VTWM2OD1\|Lki5NVU{KM7:TR?=	MV7TRW5ITVJ?
HCE-4	NXvmSZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTNwOUG2OlMh\|ryP	NHjGb25USU6JRWK=
TE-10	M4nOSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH3Cb2lKSzVyPUOuPVIxOSEQvF2=	NF;qNZdUSU6JRWK=
OVCAR-4	NVfCW4FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u5VmlEPTB;Mz65Nlg5QSEQvF2=	MoT2V2FPT0WU
ETK-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTNwOUS2N\|Uh\|ryP	M{LvdnNCVkeHUh?=
A2780	NEm2[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWnNNZZ3UUN3ME20MlA2QTZ4IN88US=>	MXvTRW5ITVJ?
LU-65	M4OyTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTRwMEe2N\|Mh\|ryP	MlyxV2FPT0WU
BHY	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPXXWdOUUN3ME20MlEzPDl3IN88US=>	NHG3PJlUSU6JRWK=
COR-L105	NYP2[VBNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TPPGlEPTB;ND6xN\|A2OSEQvF2=	NYnxdGN7W0GQR1XS
CAL-12T	NIryNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDBXlJKSzVyPUSuNVMyODNizszN	NUKwTYRqW0GQR1XS
SCH	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PWNmlEPTB;ND6xOVc1OyEQvF2=	MnjKV2FPT0WU
CW-2	NF3xfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIT6fnVKSzVyPUSuNVkxODFizszN	MX3TRW5ITVJ?
HCC1806	NVjLXmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37afWlEPTB;ND6yNFMyOiEQvF2=	MmTyV2FPT0WU
KP-N-YN	NVrFNmZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fHZmlEPTB;ND6yNFkzPyEQvF2=	NF2xWo5USU6JRWK=
T98G	Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX\yO3V{UUN3ME20MlIzOTV5IN88US=>	Mk\ZV2FPT0WU
CAL-54	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XRfGlEPTB;ND6yNlM5OSEQvF2=	NUP3RXBPW0GQR1XS
CAL-33	MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;NTWM2OD12LkKzNFY1KM7:TR?=	M2\6bHNCVkeHUh?=
SNU-C2B	M2nPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoGzTWM2OD12LkK0O\|Y6KM7:TR?=	NUDsRZZzW0GQR1XS
NUGC-3	NFXk[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzqb4E3UUN3ME20MlI2PTB3IN88US=>	NYrLe2d6W0GQR1XS
DOK	NHnFeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHuVHdZUUN3ME20MlI3PTl\|IN88US=>	NV\lRlFnW0GQR1XS
MMAC-SF	NWjR[ZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXxTWM2OD12LkK2PFU6KM7:TR?=	NUDMfIg6W0GQR1XS
KYSE-70	NWDlTGRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2TlRmlEPTB;ND6yPVM1KM7:TR?=	NUTOWJRLW0GQR1XS
A204	NWPS[mNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlTITWM2OD12LkO1PFA{KM7:TR?=	M{nKcHNCVkeHUh?=
SCC-25	NEDkNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXqRmQyUUN3ME20MlM2QDF7IN88US=>	NGDGRnpUSU6JRWK=
EPLC-272H	NUfMbnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\vSnFKSzVyPUSuN\|g6PSEQvF2=	NFPWcZhUSU6JRWK=
CAL-120	NYDGRmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Dud2lEPTB;ND6zPFk6OiEQvF2=	Mn\nV2FPT0WU
LS-513	M2\Nc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLieGxxUUN3ME20MlQzOTl6IN88US=>	NGW0N3ZUSU6JRWK=
CAPAN-1	M3jFdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnrTWM2OD12LkSyN\|gzKM7:TR?=	M3PCOHNCVkeHUh?=
ESS-1	MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTRwNEK3NlQh\|ryP	MX3TRW5ITVJ?
GMS-10	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTRwNEK4NVkh\|ryP	MUfTRW5ITVJ?
NCI-N87	NXTkS5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmnFTWM2OD12LkWwPFY5KM7:TR?=	Mo\MV2FPT0WU
HMV-II	M1j5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPKTWM2OD12LkWxO\|Mh\|ryP	NILPOoVUSU6JRWK=
COLO-741	NHXvZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHH1N4pKSzVyPUSuOVU6QTRizszN	M{LrSnNCVkeHUh?=
MKN45	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\SUmlEPTB;ND61O\|c{OiEQvF2=	MUTTRW5ITVJ?
OAW-28	M3naSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoS1TWM2OD12LkW4N\|k5KM7:TR?=	NULsRow4W0GQR1XS
OCI-AML2	NGf2eFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnfPTWM2OD12Lk[1NlM5KM7:TR?=	MkjWV2FPT0WU
MDA-MB-231	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4njTWlEPTB;ND63NFI1OyEQvF2=	NV\yO2pnW0GQR1XS
NCI-H1648	M3rhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjuSGxKSzVyPUSuO\|IzPzNizszN	MYnTRW5ITVJ?
NCI-H1792	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDvTWM2OD12Lke2NVA4KM7:TR?=	NVvjPFB1W0GQR1XS
GCIY	M3TI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHK1d2VKSzVyPUSuO\|c1OjRizszN	MYPTRW5ITVJ?
Hs-578-T	NUjDcodoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4Ds[GlEPTB;ND63O\|Y2PSEQvF2=	MYPTRW5ITVJ?
SW962	M37wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2r0e2lEPTB;ND63PFAyOSEQvF2=	NGXqXHRUSU6JRWK=
NCI-H630	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfYT4JKSzVyPUSuO\|gxQDFizszN	NITYcmdUSU6JRWK=
786-0	NV\rbW9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NY[4OnhWUUN3ME20Mlc5Pzd\|IN88US=>	NVj6VZd2W0GQR1XS
FTC-133	Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\w[lg2UUN3ME20Mlc6OjZ\|IN88US=>	NXjxVZQzW0GQR1XS
BT-20	NFjjXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33lS2lEPTB;ND63PVQzQSEQvF2=	Mn;mV2FPT0WU
Mewo	M4HOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rwbGlEPTB;ND64NVc1PyEQvF2=	M2nndHNCVkeHUh?=
SW780	M3zkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vmSGlEPTB;ND64OVc3PiEQvF2=	NIDQ[IdUSU6JRWK=
OE33	NFXCOlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTRwOEe3NVMh\|ryP	NYP3ZW5WW0GQR1XS
HCC1569	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkjaTWM2OD12Lki4OFU5KM7:TR?=	MWXTRW5ITVJ?
TE-6	NIrEbZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTRwOUO5O\|ch\|ryP	M1H0PXNCVkeHUh?=
SK-N-FI	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTRwOUS0NlEh\|ryP	M37jT3NCVkeHUh?=
PANC-03-27	NUHuT4hZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTRwOUm5OlIh\|ryP	MX\TRW5ITVJ?
MCF7	NGHZZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrWTWM2OD13LkCwO\|M5KM7:TR?=	NXfafY9iW0GQR1XS
UACC-257	NH7IdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIG0dZBKSzVyPUWuNFI5PDVizszN	MXrTRW5ITVJ?
SW1088	NGK5W2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{nqc2lEPTB;NT6wNlk1PCEQvF2=	Ml35V2FPT0WU
A704	NIGzS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTVwMEOwOkDPxE1?	MXHTRW5ITVJ?
A2058	NFn1WIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjqN\|cxUUN3ME21MlA2QTB6IN88US=>	MVTTRW5ITVJ?
Calu-3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DTbmlEPTB;NT6wOlQ2OiEQvF2=	MmfDV2FPT0WU
RERF-LC-MS	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4m0OWlEPTB;NT6wOlkxOyEQvF2=	NGTNVIhUSU6JRWK=
AU565	M3;YcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\jTIozUUN3ME21MlA6PzB{IN88US=>	NFXSfW1USU6JRWK=
DMS-79	MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTVwMUO4PFMh\|ryP	MUDTRW5ITVJ?
DK-MG	M4XWSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7FTWM2OD13LkG4OFM5KM7:TR?=	NYHSS2ZoW0GQR1XS
HuCCT1	NGTFR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjtTWM2OD13LkKzPFU3KM7:TR?=	MXrTRW5ITVJ?
HT-144	M2ey[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHxNIZsUUN3ME21MlI1QTh5IN88US=>	NV7GXWVRW0GQR1XS
M059J	M3;3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XkRmlEPTB;NT6yOVc3KM7:TR?=	MW\TRW5ITVJ?
COLO-792	M1PmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVL6[4Y1UUN3ME21MlI3OzV4IN88US=>	MlTtV2FPT0WU
SF539	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1z0RmlEPTB;NT6yOlY{OiEQvF2=	MW\TRW5ITVJ?
SK-UT-1	M{PPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvsRohKUUN3ME21MlI4PzVzIN88US=>	NIL1UIRUSU6JRWK=
NCI-H1703	NEPGU5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTVwM{W4NlYh\|ryP	MVXTRW5ITVJ?
SW837	M{PTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTlSGc4UUN3ME21MlM4QDd6IN88US=>	Mn7iV2FPT0WU
U251	NVK4Zog3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDrXWdOUUN3ME21MlM6ODl4IN88US=>	M{jFRnNCVkeHUh?=
SW1710	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTVwNEG1OVQh\|ryP	M1PnN3NCVkeHUh?=
NCI-H1299	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\qW3VzUUN3ME21MlQ3OzN3IN88US=>	M3O3W3NCVkeHUh?=
RVH-421	NVPqXlVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PkZ2lEPTB;NT60PVkxQCEQvF2=	MVvTRW5ITVJ?
UM-UC-3	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NULqfGRlUUN3ME21MlYzPjVzIN88US=>	NVHzc2x3W0GQR1XS
MDA-MB-175-VII	M2n5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFqxVpBKSzVyPUWuOlQxPDFizszN	NHnZN\|FUSU6JRWK=
KYSE-270	NGC4OJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:zW5NKSzVyPUWuOlYxOzFizszN	MoO3V2FPT0WU
COLO-668	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4O2UmlEPTB;NT63NVMzKM7:TR?=	MnHCV2FPT0WU
LN-405	M{m1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfacGNKSzVyPUWuO\|MxQDVizszN	M37iR3NCVkeHUh?=
HT-1376	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLTS4FKSzVyPUWuO\|gxPTJizszN	NHm2eoRUSU6JRWK=
769-P	M3SyOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHCVFBMUUN3ME21Mlg3PzF6IN88US=>	NHf2dZpUSU6JRWK=
HuP-T3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlyzTWM2OD13Lki4Olc4KM7:TR?=	NISwUmtUSU6JRWK=
MDA-MB-415	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vnZWlEPTB;NT65NlE{QSEQvF2=	M1XSXnNCVkeHUh?=
MKN7	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXK[nZFUUN3ME21Mlk5QCEQvF2=	MoPoV2FPT0WU
KS-1	M17pOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTCTWM2OD13Lkm4PFM3KM7:TR?=	NV[2elZ2W0GQR1XS
647-V	NH\BbpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moq3TWM2OD13Lkm5NVQ5KM7:TR?=	NFzLemxUSU6JRWK=
COLO-679	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjx[GRKSzVyPU[uNFAzPTVizszN	M{G2OHNCVkeHUh?=
AN3-CA	MkfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTZwMEO0OFEh\|ryP	M13ZWnNCVkeHUh?=
C32	Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTZwMUOwN\|Qh\|ryP	MkLQV2FPT0WU
KM12	NIPVNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfhXWtRUUN3ME22MlI1ODl7IN88US=>	Ml3mV2FPT0WU
KINGS-1	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfGO4pCUUN3ME22MlI3OTV{IN88US=>	NFTFcpBUSU6JRWK=
KYSE-410	NH7FdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUCzU25FUUN3ME22MlMxPjR3IN88US=>	NX;TOoNRW0GQR1XS
HPAF-II	MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTZwM{W0PEDPxE1?	MmHWV2FPT0WU
LAN-6	MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnWwTWM2OD14LkS5OlMyKM7:TR?=	M1L2OnNCVkeHUh?=
LU-99A	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVTqUo1TUUN3ME22MlU2QTh7IN88US=>	M1HEWHNCVkeHUh?=
SJSA-1	NUHLOIdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjtZYdKSzVyPU[uOVY{PDdizszN	NGLB[mdUSU6JRWK=
MSTO-211H	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjRXYNKSzVyPU[uO\|IzOzNizszN	MYDTRW5ITVJ?
SW900	NYH1d2U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrZPFJKSzVyPU[uO\|YzOjFizszN	MmjaV2FPT0WU
LNCaP-Clone-FGC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWe3enE5UUN3ME22MlgxPDB\|IN88US=>	M1nFUHNCVkeHUh?=
OMC-1	NHjvc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXnTWM2OD14Lki1OFAzKM7:TR?=	NGfDeGNUSU6JRWK=
IST-MEL1	NV;kN2NPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33YbGlEPTB;Nj64PVY3QSEQvF2=	NF;PZ\|RUSU6JRWK=
TE-9	MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\0NpBNUUN3ME22Mlg6QDR5IN88US=>	MkjRV2FPT0WU
NCI-H2030	NWfV[5U1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTZwOUGyNlYh\|ryP	MVLTRW5ITVJ?
BFTC-909	M3z1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnEfZVKSzVyPUeuNFA3PDFizszN	MknsV2FPT0WU
NCI-SNU-5	M1XPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTdwMEKxOVkh\|ryP	NHnpVXdUSU6JRWK=
TE-5	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPveZFKSzVyPUeuNFI5QDFizszN	NV75WJZlW0GQR1XS
SK-MES-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTdwMEW0Nlch\|ryP	NUjzPYMxW0GQR1XS
SHP-77	M2[xN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPIPXA2UUN3ME23MlE{QTV{IN88US=>	M4DzdHNCVkeHUh?=
NCI-H1623	NVn0WJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfze5hSUUN3ME23MlE1ODd{IN88US=>	MmjpV2FPT0WU
TE-11	MlnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TVdGlEPTB;Nz6xOVE5PCEQvF2=	M1\SNnNCVkeHUh?=
EKVX	NH[1RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDoSplIUUN3ME23MlE6OjZ5IN88US=>	NYm4O4pxW0GQR1XS
OVCAR-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHKzc\|JKSzVyPUeuNlEyOzNizszN	NFjiPHdUSU6JRWK=
C3A	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\l[G5KSzVyPUeuN\|Q2OiEQvF2=	MVHTRW5ITVJ?
CFPAC-1	MoDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvlcIdKSzVyPUeuN\|YzOjJizszN	NHXKVZhUSU6JRWK=
MG-63	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLZTWM2OD15LkSxPFQ6KM7:TR?=	NUX6UJYzW0GQR1XS
KYSE-140	NEfVb3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4X4NmlEPTB;Nz60OFA3OSEQvF2=	NWj0VWliW0GQR1XS
MPP-89	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTdwNUm3Nlkh\|ryP	MYXTRW5ITVJ?
COLO-824	NGSzN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTdwN{K4OlMh\|ryP	MkjlV2FPT0WU
SiHa	M1K1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\xcoFKSzVyPUeuPFM4ODdizszN	MnXCV2FPT0WU
SNU-387	MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LwR2lEPTB;Nz64OVM1PyEQvF2=	MWnTRW5ITVJ?
A172	NXfnRZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHqyPWtKSzVyPUeuPFYyPzJizszN	MYTTRW5ITVJ?
COLO-680N	NUTBZVZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4i1[GlEPTB;Nz65NVc{KM7:TR?=	MV7TRW5ITVJ?
HCC1395	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRThwMEW0OVIh\|ryP	NEHF[YVUSU6JRWK=
NCI-H28	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPyWG57UUN3ME24MlA2QTZ\|IN88US=>	NWTkc5J2W0GQR1XS
LC-2-ad	NYOwVYhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRThwMkG5N\|ch\|ryP	MYLTRW5ITVJ?
S-117	NYTScIl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjRc\|hKSzVyPUiuNlU{PTNizszN	MlSxV2FPT0WU
NCI-H1838	M3yxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\SN2lEPTB;OD6yOVc5OSEQvF2=	M1XzXXNCVkeHUh?=
PANC-10-05	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2S0TmlEPTB;OD6zO\|A1PyEQvF2=	M4r6OnNCVkeHUh?=
KALS-1	MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\LeVFUUUN3ME24MlUxQTJ6IN88US=>	NYfIZ\|JOW0GQR1XS
LS-1034	NFPIUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRThwNUe0N\|ch\|ryP	NX;CNohKW0GQR1XS
TGBC1TKB	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRThwN{O1N\|Uh\|ryP	MVTTRW5ITVJ?
OE19	NGKyXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRThwN{[yOlIh\|ryP	MlroV2FPT0WU
D-502MG	MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPlUoRyUUN3ME24Mlc3QTl2IN88US=>	M1rnSnNCVkeHUh?=
JEG-3	MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml31TWM2OD16Lke4OlE5KM7:TR?=	M1jZcXNCVkeHUh?=
DBTRG-05MG	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2HLeGlEPTB;OD64O\|U3PSEQvF2=	MmPIV2FPT0WU
ME-180	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTlwME[3NlUh\|ryP	M3XhO3NCVkeHUh?=
NCI-H1573	NWjQbnY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\jXGlEPTB;OT6xNFU{OiEQvF2=	NH21[Y5USU6JRWK=
HCC2998	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M162fmlEPTB;OT6xN\|Y5OSEQvF2=	NGS5cGxUSU6JRWK=
ACHN	M1P1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXywUoZHUUN3ME25MlI1QTd3IN88US=>	MWXTRW5ITVJ?
D-392MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHrTWM2OD17LkK1O\|E2KM7:TR?=	MXHTRW5ITVJ?
no-11	M{flV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKzWWlKSzVyPUmuNlYxOjhizszN	NWq0TG5kW0GQR1XS
KLE	NU\3W2lDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTlwM{KyN\|Ih\|ryP	MnPZV2FPT0WU
Calu-6	NH;uV5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIL0XnZKSzVyPUmuN\|c2OjhizszN	NVTYUlE1W0GQR1XS
LB831-BLC	NFnQUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTlwNEWxO\|Eh\|ryP	M3LHO3NCVkeHUh?=
SW684	NWXFSWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknyTWM2OD17LkS2NVE3KM7:TR?=	Mn\QV2FPT0WU
SH-4	M13KTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nVSWlEPTB;OT60PVM3PCEQvF2=	Ml;mV2FPT0WU
IST-MES1	NHLSfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTlT5AxUUN3ME25MlUyPjR2IN88US=>	NY\oTIV7W0GQR1XS
Saos-2	M4\NVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4njWmlEPTB;OT61NlE6PSEQvF2=	NFW5e4hUSU6JRWK=
NCI-H2087	NXG3Xld5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHG2O3FKSzVyPUmuOlc{PTJizszN	NWXTd\|RoW0GQR1XS
SCC-9	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTlwN{G4NVYh\|ryP	MUHTRW5ITVJ?
MFE-280	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofQTWM2OD17LkeyO\|g2KM7:TR?=	MmHvV2FPT0WU
BEN	NEDhNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XqXmlEPTB;OT64NlE2QSEQvF2=	NFHVSXdUSU6JRWK=
CP50-MEL-B	NY\hRWRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\2TGlEPTB;OT65NlQ{OiEQvF2=	MWnTRW5ITVJ?
SK-MEL-28	M2fOOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVTYOVBKUUN3ME2xNE4xOTl\|IN88US=>	NX\DV\|lGW0GQR1XS
NCI-H2452	MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXUclNKSzVyPUGwMlE3KM7:TR?=	M{LzWHNCVkeHUh?=
NCI-H1395	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnKfGlTUUN3ME2xNE4yPzhizszN	NGW4[4FUSU6JRWK=
NCI-H2052	M3nQ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\aSJhlUUN3ME2xNE4yQDh{IN88US=>	MofIV2FPT0WU
A375	NWjyc2ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP1TWM2OD1zMD6yOFUzKM7:TR?=	NF;SZlhUSU6JRWK=
HCC38	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LvT2lEPTB;MUCuN\|IzKM7:TR?=	MXvTRW5ITVJ?
LK-2	MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{X4N2lEPTB;MUCuOFIxQCEQvF2=	MljaV2FPT0WU
SF126	MmLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfKZmxrUUN3ME2xNE41PzJ5IN88US=>	MULTRW5ITVJ?
SK-MEL-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTFyLke4N\|gh\|ryP	MVTTRW5ITVJ?
ACN	M{fUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkH3TWM2OD1zMD64Olc6KM7:TR?=	NHe5XVRUSU6JRWK=
BB30-HNC	NV63c4g{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;5T\|BlUUN3ME2xNE45PzFzIN88US=>	NYfYTGoxW0GQR1XS
NCI-H747	NIW0cZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTFyLki3OFYh\|ryP	NUXxO4tsW0GQR1XS
KYSE-150	M{TXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1PKd2lEPTB;MUGuNFM5PyEQvF2=	NUHmVnNHW0GQR1XS
D-247MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojZTWM2OD1zMT6xNFA6KM7:TR?=	M2S0WnNCVkeHUh?=
BxPC-3	NVXkNJA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWn6WI1sUUN3ME2xNU4{PzR5IN88US=>	MXLTRW5ITVJ?
SK-MEL-30	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nuU2lEPTB;MUGuOFA4QSEQvF2=	NFfPUWZUSU6JRWK=
CAS-1	NXrCepg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHL2e\|VKSzVyPUGxMlQyODlizszN	NHPsdIdUSU6JRWK=
no-10	M1;ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17KOmlEPTB;MUKuNVIyPyEQvF2=	M1zoU3NCVkeHUh?=
NCI-H2405	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTvTWM2OD1zMj6yNFM3KM7:TR?=	NYWzbFVUW0GQR1XS
KGN	M3XLN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LaTGlEPTB;MUKuNlkxOSEQvF2=	MWXTRW5ITVJ?
BB49-HNC	NIG4SZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPCOJd4UUN3ME2xNk4{QTV4IN88US=>	MXHTRW5ITVJ?
NCI-H1693	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTF{LkW4NVYh\|ryP	MlrEV2FPT0WU
RO82-W-1	NGH3ZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{fvO2lEPTB;MUOuNFY1QSEQvF2=	MXrTRW5ITVJ?
CAL-85-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml36TWM2OD1zMz60N\|k6KM7:TR?=	NH3uW2lUSU6JRWK=
H-EMC-SS	NXvOWmtLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HhR2lEPTB;MUOuPVExPCEQvF2=	NH6zTmlUSU6JRWK=
SW1783	NEHiWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTF2LkKzPVEh\|ryP	NHS4NZpUSU6JRWK=
LB771-HNC	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\j[WlEPTB;MUSuOFE6KM7:TR?=	NIL3TpFUSU6JRWK=
HCC70	NIqwfFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTObo56UUN3ME2xOE41OjN\|IN88US=>	NI\sSZRUSU6JRWK=
KNS-81-FD	NYXwVGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkm2TWM2OD1zND63NFQ2KM7:TR?=	NH;kOY9USU6JRWK=
KYSE-520	M2rGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\XSGlEPTB;MUSuPVI4KM7:TR?=	NHjWSGhUSU6JRWK=
TGBC24TKB	M4\0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTF2Lkm1N\|kh\|ryP	MlnSV2FPT0WU
SNB75	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXPTWM2OD1zNT6wO\|I6KM7:TR?=	NYTNPW5qW0GQR1XS
SW872	MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7SPGJKSzVyPUG1MlIzOThizszN	NWf4fFNjW0GQR1XS
U031	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4D4VGlEPTB;MUWuPFAzQCEQvF2=	M2nMTnNCVkeHUh?=
ChaGo-K-1	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS4PXRUUUN3ME2xOU45OzV7IN88US=>	MkXpV2FPT0WU
NCI-H441	NHPaNnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mki4TWM2OD1zNj6wNFM6KM7:TR?=	NFrTenpUSU6JRWK=
TE-12	NIXOUFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M334WGlEPTB;MU[uNVg4OyEQvF2=	MVXTRW5ITVJ?
NCI-H1755	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofNTWM2OD1zNj61O\|Mh\|ryP	NIDBdmJUSU6JRWK=
KNS-42	NHq0UndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnZbVZUUUN3ME2xOk43PTh7IN88US=>	MoXPV2FPT0WU
SK-PN-DW	NVzOUYNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLJR\|UxRTF5LkSyNFEh\|ryP	M3PIOXNCVkeHUh?=
NCI-H226	M4rlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3GUlZKSzVyPUG3Mlk{PDVizszN	NVy5[FcxW0GQR1XS
K-562	M1G2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\QNY1KSzVyPUG4MlY{OTdizszN	NYjqTVNOW0GQR1XS
A388	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXf0eJpmUUN3ME2xPU4xOzB\|IN88US=>	MXXTRW5ITVJ?
ZR-75-30	NEnHbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnr3TWM2OD1zOT6wPVY5KM7:TR?=	NVHXfpFHW0GQR1XS
LU-135	NVXCW5ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXj0W3NZUUN3ME2xPU4zPjN4IN88US=>	NHHXZYNUSU6JRWK=
NCI-H2029	NEiwVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTF7Lk[wNlEh\|ryP	NYDSS4VTW0GQR1XS
HT-1197	M2\OR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTF7LkmyNlch\|ryP	NWfUUll6W0GQR1XS
IGR-1	NXTYOYZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJyLkOxNVch\|ryP	NGew[HZUSU6JRWK=
U-87-MG	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;LOlk4UUN3ME2yNE43PDF\|IN88US=>	MkjkV2FPT0WU
NCI-H1304	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTJyLke1NFEh\|ryP	M{fi[XNCVkeHUh?=
RCC10RGB	NUHwbXQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfmfW5tUUN3ME2yNU4zQDJ7IN88US=>	MXvTRW5ITVJ?
NCI-H520	M{f6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPYTWM2OD1{Mj63OlEyKM7:TR?=	NHO5WpdUSU6JRWK=
SK-LU-1	NYHIXZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTJ\|LkC3NVgh\|ryP	NF;PR5VUSU6JRWK=
UACC-893	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTJ\|LkGwN\|gh\|ryP	MnH1V2FPT0WU
NCI-H2347	NGiw[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH2RYxKSzVyPUKzMlI3PzRizszN	NGXqXJdUSU6JRWK=
U-118-MG	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nmNmlEPTB;MkOuO\|IyPyEQvF2=	MYLTRW5ITVJ?
NCI-H596	M3:3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzpW2NKSzVyPUKzMlkxPTVizszN	NEXCVFNUSU6JRWK=
MZ1-PC	NV20ZoY3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTJ2Lk[3OVkh\|ryP	NYHQU2Q2W0GQR1XS
SW1417	NIPWRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:yWZlKSzVyPUK1MlI1QThizszN	MVnTRW5ITVJ?
NCI-H82	M{fhbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJ4LkSyPFgh\|ryP	M{DBXnNCVkeHUh?=
COLO-678	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlP1TWM2OD1{Nz60PVE6KM7:TR?=	NV\xeGxTW0GQR1XS
KURAMOCHI	NEHmZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHEZ4ZKSzVyPUK4MlEzPiEQvF2=	NYPVbZVlW0GQR1XS
NCI-H1650	NWm3d\|N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkC0TWM2OD1\|MD6xPVI1KM7:TR?=	NYfWbHYzW0GQR1XS
HCC1954	MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTNzLkO2OlYh\|ryP	MkPQV2FPT0WU
GAK	M{\0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HwR2lEPTB;M{KuNlYyPiEQvF2=	Mke5V2FPT0WU
YAPC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\PTpNKSzVyPUOzMlc3PDhizszN	M3;aPHNCVkeHUh?=
NCI-H2228	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLNVotJUUN3ME2zOE4{PjB3IN88US=>	MnnsV2FPT0WU
VMRC-RCZ	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvubVNKSzVyPUO2MlMxOjJizszN	NGHvRldUSU6JRWK=
NMC-G1	MkHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnGWXhqUUN3ME2zO{4xPTJ7IN88US=>	MnuyV2FPT0WU
D-336MG	MkjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUW5S3R4UUN3ME20NU45PDR{IN88US=>	MmrjV2FPT0WU
UACC-62	M13WcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\S[WlEPTB;NEKuOVUxPSEQvF2=	M17HVnNCVkeHUh?=
C-33-A	NEH0e\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfYXlhTUUN3ME20OU4{OjV4IN88US=>	NGnse\|RUSU6JRWK=
HCC1937	Mm[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NELoRlZKSzVyPUS3MlE6PThizszN	M1PCenNCVkeHUh?=
HDLM-2	NXPqdnZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTR5LkKyPFch\|ryP	M4nWSXNCVkeHUh?=
NCI-H727	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MluxTWM2OD12Nz6yOFUyKM7:TR?=	MmjyV2FPT0WU
NY	NUnaPVJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPqTWM2OD12OT6zPVA5KM7:TR?=	NELQXWdUSU6JRWK=
NCI-H2291	M3P0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWr2eoVMUUN3ME20PU45OzBzIN88US=>	M{DROXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	- Collapse Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Suspended	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 211 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 211 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)